z,Precipitant Type,Precipitant,Precipitant Annotator,Precipitant Span Start,Precipitant SpanEnd,Object Type,Object,Object Annotator,Metabolite,Object Span Start,Object Span End,Modality,Interaction Phrase Type,Interaction Phrase,Interaction Phrase Annotator,Interaction Phrase Span Start,Interaction Phrase Span End
package-insert-section-1.txt,Active ingredient,tenofovir ,consensus set annotator team,367,376,Active ingredient,didanosine ,consensus set annotator team,,318,328,Positive,Qualitative,"Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].",consensus set annotator team,306,341
package-insert-section-100.txt,Active ingredient,Carbamazepine ,consensus set annotator team,45,58,Active ingredient,alprazolam ,consensus set annotator team,,138,148,Positive,Qualitative,"Drugs demonstrated to be inducers of CYP3A

 Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam. ",consensus set annotator team,63,93
package-insert-section-102.txt,Active ingredient,metoclopramide ,consensus set annotator team,802,816,Active ingredient,digoxin ,consensus set annotator team,,824,831,Positive,Qualitative,"7.3 Drug Absorption

Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).",consensus set annotator team,744,798
package-insert-section-102.txt,Active ingredient,metoclopramide ,consensus set annotator team,802,816,Active ingredient,levodopa ,consensus set annotator team,,962,970,Positive,Qualitative,"7.3 Drug Absorption

Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).",consensus set annotator team,842,925
package-insert-section-102.txt,Active ingredient,metoclopramide ,consensus set annotator team,802,816,Active ingredient,ethanol ,consensus set annotator team,,972,979,Positive,Qualitative,"7.3 Drug Absorption

Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).",consensus set annotator team,842,925
package-insert-section-102.txt,Active ingredient,metoclopramide ,consensus set annotator team,802,816,Active ingredient,cyclosporine ,consensus set annotator team,,981,993,Positive,Qualitative,"7.3 Drug Absorption

Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).",consensus set annotator team,842,925
package-insert-section-102.txt,Active ingredient,metoclopramide ,consensus set annotator team,802,816,Active ingredient,tetracycline ,consensus set annotator team,,948,960,Positive,Qualitative,"7.3 Drug Absorption

Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).",consensus set annotator team,842,925
package-insert-section-102.txt,Active ingredient,metoclopramide ,consensus set annotator team,802,816,Active ingredient,acetaminophen ,consensus set annotator team,,933,946,Positive,Qualitative,"7.3 Drug Absorption

Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).",consensus set annotator team,842,925
package-insert-section-104.txt,Active ingredient,ketoconazole ,consensus set annotator team,267,279,Active ingredient,conivaptan ,consensus set annotator team,,231,241,Positive,Quantitative,"Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively [see Contraindications (4.2)].",consensus set annotator team,287,339
package-insert-section-104.txt,Drug product,VAPRISOL ,consensus set annotator team,648,656,Active ingredient,midazolam ,consensus set annotator team,,771,780,Positive,Quantitative,"VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively.",consensus set annotator team,667,727
package-insert-section-104.txt,Drug product,VAPRISOL ,consensus set annotator team,796,804,Active ingredient,simvastatin ,consensus set annotator team,,859,870,Positive,Quantitative,VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin.,consensus set annotator team,815,870
package-insert-section-104.txt,Active ingredient,conivaptan ,consensus set annotator team,877,887,Active ingredient,amlodipine ,consensus set annotator team,,978,988,Positive,Quantitative,Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].,consensus set annotator team,932,974
package-insert-section-104.txt,Active ingredient,conivaptan ,consensus set annotator team,1125,1135,Active ingredient,digoxin ,consensus set annotator team,,1078,1085,Positive,Quantitative,"7.2 Digoxin

Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].",consensus set annotator team,1180,1258
package-insert-section-104.txt,Drug product,VAPRISOL ,consensus set annotator team,1333,1341,Active ingredient,warfarin ,consensus set annotator team,,1406,1414,Positive,Quantitative,"7.3 Warfarin

VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.",consensus set annotator team,1490,1572
package-insert-section-104.txt,Active ingredient,captopril ,consensus set annotator team,1802,1811,Active ingredient,conivaptan ,consensus set annotator team,,1727,1737,Negative,Qualitative,"7.4 Captopril and Furosemide

The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.",consensus set annotator team,1698,1769
package-insert-section-104.txt,Active ingredient,furosemide ,consensus set annotator team,1821,1831,Active ingredient,conivaptan ,consensus set annotator team,,1727,1737,Negative,Qualitative,"7.4 Captopril and Furosemide

The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.",consensus set annotator team,1698,1769
package-insert-section-106.txt,Active ingredient,quinidine ,consensus set annotator team,444,453,Active ingredient,metoprolol ,consensus set annotator team,,518,528,Positive,Qualitative,"7.2 CYP2D6 Inhibitors

Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.",consensus set annotator team,495,517
package-insert-section-106.txt,Active ingredient,fluoxetine ,consensus set annotator team,455,465,Active ingredient,metoprolol ,consensus set annotator team,,518,528,Positive,Qualitative,"7.2 CYP2D6 Inhibitors

Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.",consensus set annotator team,495,517
package-insert-section-106.txt,Active ingredient,paroxetine ,consensus set annotator team,467,477,Active ingredient,metoprolol ,consensus set annotator team,,518,528,Positive,Qualitative,"7.2 CYP2D6 Inhibitors

Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.",consensus set annotator team,495,517
package-insert-section-106.txt,Active ingredient,propafenone ,consensus set annotator team,483,494,Active ingredient,metoprolol ,consensus set annotator team,,518,528,Positive,Qualitative,"7.2 CYP2D6 Inhibitors

Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.",consensus set annotator team,495,517
package-insert-section-106.txt,Active ingredient,quinidine ,consensus set annotator team,629,638,Active ingredient,metoprolol ,consensus set annotator team,,668,678,Positive,Quantitative,"In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life.",consensus set annotator team,686,776
package-insert-section-106.txt,Active ingredient,propafenone ,consensus set annotator team,844,855,Active ingredient,metoprolol ,consensus set annotator team,,893,903,Positive,Quantitative,"In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d.with immediate-release metoprolol 50 mg t.i.d.resulted in two- to five-fold increases in the steady-state concentration of metoprolol.",consensus set annotator team,917,1004
package-insert-section-108.txt,Active ingredient,quinidine ,consensus set annotator team,130,139,Active ingredient,nifedipine ,consensus set annotator team,,168,178,Positive,Quantitative,"Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.",consensus set annotator team,194,280
package-insert-section-108.txt,Active ingredient,nifedipine ,consensus set annotator team,476,486,Active ingredient,quinidine ,consensus set annotator team,,419,428,Negative,Qualitative,The exposure to quinidine was not importantly changed in the presence of nifedipine.,consensus set annotator team,407,456
package-insert-section-109.txt,Active ingredient,diltiazem ,consensus set annotator team,74,83,Active ingredient,nifedipine ,consensus set annotator team,,235,245,Positive,Quantitative,"Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d.diltiazem p.o.increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively.",consensus set annotator team,220,281
package-insert-section-11.txt,Active ingredient,cimetidine ,consensus set annotator team,83,93,Active ingredient,sertraline ,consensus set annotator team,,161,171,Positive,Quantitative,"In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group.",consensus set annotator team,148,217
package-insert-section-110.txt,Active ingredient,nifedipine ,consensus set annotator team,166,176,Active ingredient,irbesartan ,consensus set annotator team,,194,204,Negative,Qualitative,"However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics.",consensus set annotator team,177,221
package-insert-section-111.txt,Active ingredient,nifedipine ,consensus set annotator team,202,212,Active ingredient,doxazosin ,consensus set annotator team,,255,264,Positive,Quantitative,"Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively.",consensus set annotator team,213,279
package-insert-section-111.txt,Active ingredient,doxazosin ,consensus set annotator team,357,366,Active ingredient,nifedipine ,consensus set annotator team,,384,394,Positive,Quantitative,"In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively.",consensus set annotator team,368,437
package-insert-section-113.txt,Active ingredient,cimetidine ,consensus set annotator team,417,427,Active ingredient,nifedipine ,consensus set annotator team,,465,475,Positive,Quantitative,"In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d.alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine.",consensus set annotator team,451,559
package-insert-section-113.txt,Active ingredient,cimetidine ,consensus set annotator team,624,634,Active ingredient,nifedipine ,consensus set annotator team,,594,604,Positive,Quantitative,The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02.,consensus set annotator team,579,690
package-insert-section-114.txt,Active ingredient,quinupristin ,consensus set annotator team,198,210,Active ingredient,nifedipine ,consensus set annotator team,,228,238,Positive,Quantitative,"Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy.",consensus set annotator team,282,347
package-insert-section-114.txt,Active ingredient,dalfopristin ,consensus set annotator team,211,223,Active ingredient,nifedipine ,consensus set annotator team,,228,238,Positive,Quantitative,"Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy.",consensus set annotator team,282,347
package-insert-section-115.txt,Active ingredient,phenytoin ,consensus set annotator team,136,145,Active ingredient,nifedipine ,consensus set annotator team,,68,78,Positive,Quantitative,"Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%.",consensus set annotator team,169,228
package-insert-section-116.txt,Active ingredient,rosiglitazone ,consensus set annotator team,36,49,Active ingredient,nifedipine ,consensus set annotator team,,139,149,Negative,Qualitative,Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.)was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.,consensus set annotator team,68,135
package-insert-section-118.txt,Drug product,Synercid ,consensus set annotator team,30,38,Active ingredient,nifedipine ,consensus set annotator team,,282,292,Positive,Quantitative,Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.,consensus set annotator team,195,276
package-insert-section-118.txt,Drug product,Synercid ,consensus set annotator team,30,38,Active ingredient,midazolam ,consensus set annotator team,,297,306,Positive,Quantitative,Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.,consensus set annotator team,195,276
package-insert-section-12.txt,Active ingredient,sertraline ,consensus set annotator team,123,133,Active ingredient,diazepam ,consensus set annotator team,,230,238,Positive,Quantitative,"In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03).",consensus set annotator team,193,248
package-insert-section-12.txt,Active ingredient,sertraline ,consensus set annotator team,419,429,Metabolite,desmethyldiazepam ,consensus set annotator team,diazepam ,394,411,Positive,Quantitative,There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03).,consensus set annotator team,368,389
package-insert-section-122.txt,Active ingredient,rifampin ,consensus set annotator team,170,178,Active ingredient,rosiglitazone ,consensus set annotator team,,204,217,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2C8 Inhibitors and Inducers

An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone.",consensus set annotator team,180,200
package-insert-section-122.txt,Active ingredient,gemfibrozil ,consensus set annotator team,87,98,Active ingredient,rosiglitazone ,consensus set annotator team,,124,137,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2C8 Inhibitors and Inducers

An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone.",consensus set annotator team,100,120
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,9050,9057,Active ingredient,nifedipine ,consensus set annotator team,,9152,9162,Negative,Qualitative,"AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.",consensus set annotator team,9077,9124
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,9050,9057,Active ingredient,nifedipine ,consensus set annotator team,,9152,9162,Negative,Qualitative,"AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.",consensus set annotator team,9095,9148
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,9050,9057,Active ingredient,norethindrone ,consensus set annotator team,,9210,9223,Negative,Qualitative,"AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.",consensus set annotator team,9077,9124
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,9050,9057,Active ingredient,ethinyl estradiol ,consensus set annotator team,,9188,9205,Negative,Qualitative,"AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.",consensus set annotator team,9095,9148
package-insert-section-123.txt,Active ingredient,gemfibrozil ,consensus set annotator team,9317,9328,Active ingredient,rosiglitazone ,consensus set annotator team,,9379,9392,Positive,Quantitative,"Gemfibrozil

Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.",consensus set annotator team,9422,9457
package-insert-section-123.txt,Active ingredient,Rifampin ,consensus set annotator team,9731,9739,Active ingredient,rosiglitazone ,consensus set annotator team,,9833,9846,Positive,Quantitative,"Rifampin

Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4

Glyburide

AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.",consensus set annotator team,9824,9857
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,10201,10208,Active ingredient,glyburide ,consensus set annotator team,,10295,10304,Positive,Quantitative,Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.,consensus set annotator team,10283,10338
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,10434,10441,Active ingredient,glyburide ,consensus set annotator team,,10362,10371,Positive,Qualitative,"Glimepiride

Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.",consensus set annotator team,10372,10403
package-insert-section-123.txt,Active ingredient,glimepiride ,consensus set annotator team,10478,10489,Drug product,AVANDIA ,consensus set annotator team,,10596,10603,Negative,Qualitative,"Glimepiride

Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.",consensus set annotator team,10519,10603
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,10706,10713,Active ingredient,glimepiride ,consensus set annotator team,,10645,10656,Negative,Quantitative,No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.,consensus set annotator team,10605,10683
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,10811,10818,Active ingredient,metformin ,consensus set annotator team,,10842,10851,Negative,Qualitative,"Metformin

Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.",consensus set annotator team,10906,10956
package-insert-section-123.txt,Active ingredient,metformin ,consensus set annotator team,10842,10851,Drug product,AVANDIA ,consensus set annotator team,,10811,10818,Negative,Qualitative,"Metformin

Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.",consensus set annotator team,10906,10956
package-insert-section-123.txt,Active ingredient,acarbose ,consensus set annotator team,11026,11034,Drug product,AVANDIA ,consensus set annotator team,,11178,11185,Negative,Qualitative,"Acarbose

Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.",consensus set annotator team,11095,11152
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,11219,11226,Active ingredient,digoxin ,consensus set annotator team,,11308,11315,Negative,Qualitative,"Digoxin

Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.",consensus set annotator team,11257,11304
package-insert-section-123.txt,Drug product,AVANDIA ,consensus set annotator team,11391,11398,Active ingredient,warfarin ,consensus set annotator team,,11473,11481,Negative,Qualitative,"Warfarin

Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.",consensus set annotator team,11399,11469
package-insert-section-123.txt,Active ingredient,ranitidine ,consensus set annotator team,11699,11709,Active ingredient,rosiglitazone ,consensus set annotator team,,11823,11836,Negative,Qualitative,"Ranitidine

Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.",consensus set annotator team,11742,11776
package-insert-section-124.txt,Active ingredient,propranolol ,consensus set annotator team,78,89,Active ingredient,propafenone ,consensus set annotator team,,11,22,Positive,Quantitative,The AUC of propafenone is increased by more than 200% by co-administration of propranolol.,consensus set annotator team,0,53
package-insert-section-125.txt,Active ingredient,quinidine ,consensus set annotator team,65,74,Active ingredient,propranolol ,consensus set annotator team,,18,29,Positive,Qualitative,"The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.",consensus set annotator team,4,40
package-insert-section-126.txt,Active ingredient,propranolol ,consensus set annotator team,104,115,Active ingredient,nifedipine ,consensus set annotator team,,25,35,Positive,Quantitative,"The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.",consensus set annotator team,9,64
package-insert-section-127.txt,Active ingredient,Propranolol ,consensus set annotator team,0,11,Active ingredient,verapamil ,consensus set annotator team,,52,61,Negative,Qualitative,Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.,consensus set annotator team,12,48
package-insert-section-127.txt,Active ingredient,Propranolol ,consensus set annotator team,0,11,Metabolite,norverapamil ,consensus set annotator team,verapamil ,66,78,Negative,Qualitative,Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.,consensus set annotator team,12,48
package-insert-section-127.txt,Active ingredient,Verapamil ,consensus set annotator team,80,89,Active ingredient,propranolol ,consensus set annotator team,,130,141,Negative,Qualitative,Verapamil does not affect the pharmacokinetics of propranolol.,consensus set annotator team,90,126
package-insert-section-128.txt,Active ingredient,Propranolol ,consensus set annotator team,0,11,Active ingredient,diazepam ,consensus set annotator team,,42,50,Positive,Qualitative,"Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.",consensus set annotator team,12,38
package-insert-section-128.txt,Active ingredient,Diazepam ,consensus set annotator team,123,131,Active ingredient,propranolol ,consensus set annotator team,,171,182,Negative,Qualitative,Diazepam does not alter the pharmacokinetics of propranolol.,consensus set annotator team,132,167
package-insert-section-129.txt,Active ingredient,cimetidine ,consensus set annotator team,38,48,Active ingredient,propranolol ,consensus set annotator team,,21,32,Positive,Quantitative,"Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.",consensus set annotator team,83,132
package-insert-section-129.txt,Active ingredient,aluminum hydroxide ,consensus set annotator team,171,189,Active ingredient,propranolol ,consensus set annotator team,,232,243,Positive,Qualitative,Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.,consensus set annotator team,220,258
package-insert-section-13.txt,Active ingredient,sertraline ,consensus set annotator team,87,97,Active ingredient,lithium ,consensus set annotator team,,139,146,Negative,Qualitative,"In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.",consensus set annotator team,98,176
package-insert-section-130.txt,Active ingredient,metoclopramide ,consensus set annotator team,21,35,Active ingredient,propranolol ,consensus set annotator team,,57,68,Negative,Qualitative,Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolols pharmacokinetics.,consensus set annotator team,69,136
package-insert-section-131.txt,Active ingredient,cholestyramine ,consensus set annotator team,21,35,Active ingredient,propranolol ,consensus set annotator team,,55,66,Positive,Quantitative,Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.,consensus set annotator team,85,127
package-insert-section-131.txt,Active ingredient,colestipol ,consensus set annotator team,39,49,Active ingredient,propranolol ,consensus set annotator team,,55,66,Positive,Quantitative,Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.,consensus set annotator team,85,127
package-insert-section-132.txt,Active ingredient,propranolol ,consensus set annotator team,21,32,Active ingredient,lovastatin ,consensus set annotator team,,38,48,Positive,Quantitative,"Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.",consensus set annotator team,65,93
package-insert-section-132.txt,Active ingredient,propranolol ,consensus set annotator team,21,32,Active ingredient,pravastatin ,consensus set annotator team,,52,63,Positive,Quantitative,"Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.",consensus set annotator team,65,93
package-insert-section-132.txt,Active ingredient,Propranolol ,consensus set annotator team,145,156,Active ingredient,fluvastatin ,consensus set annotator team,,207,218,Negative,Qualitative,Propranolol did not have an effect on the pharmacokinetics of fluvastatin.,consensus set annotator team,161,203
package-insert-section-133.txt,Active ingredient,propranolol ,consensus set annotator team,33,44,Active ingredient,thioridazine ,consensus set annotator team,,112,124,Positive,Quantitative,Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.,consensus set annotator team,102,171
package-insert-section-133.txt,Active ingredient,propranolol ,consensus set annotator team,33,44,Metabolite,mesoridazine ,consensus set annotator team,thioridazine ,211,223,Positive,Quantitative,Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.,consensus set annotator team,176,264
package-insert-section-134.txt,Active ingredient,chlorpromazine ,consensus set annotator team,21,35,Active ingredient,propranolol ,consensus set annotator team,,41,52,Positive,Quantitative,Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.,consensus set annotator team,53,107
package-insert-section-136.txt,Active ingredient,ritonavir ,consensus set annotator team,194,203,Active ingredient,trazodone ,consensus set annotator team,,117,126,Positive,Qualitative,"In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.",consensus set annotator team,138,154
package-insert-section-136.txt,Active ingredient,indinavir ,consensus set annotator team,209,218,Active ingredient,trazodone ,consensus set annotator team,,117,126,Positive,Qualitative,"In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.",consensus set annotator team,138,154
package-insert-section-136.txt,Active ingredient,ritonavir ,consensus set annotator team,263,272,Active ingredient,trazodone ,consensus set annotator team,,347,356,Positive,Quantitative,"The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects.",consensus set annotator team,410,545
package-insert-section-137.txt,Active ingredient,carbamazepine ,consensus set annotator team,124,137,Active ingredient,trazodone ,consensus set annotator team,,171,180,Positive,Quantitative,"Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.",consensus set annotator team,138,226
package-insert-section-137.txt,Active ingredient,carbamazepine ,consensus set annotator team,124,137,Metabolite,mCPP ,consensus set annotator team,trazodone ,193,197,Positive,Quantitative,"Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.",consensus set annotator team,138,226
package-insert-section-139.txt,Active ingredient,aluminum ,consensus set annotator team,273,281,Active ingredient,fexofenadine ,consensus set annotator team,,202,214,Positive,Quantitative,"In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2  60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox1) decreased fexofenadine AUC by 41% and Cmax by 43%.",consensus set annotator team,326,375
package-insert-section-139.txt,Active ingredient,magnesium ,consensus set annotator team,286,295,Active ingredient,fexofenadine ,consensus set annotator team,,202,214,Positive,Quantitative,"In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2  60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox1) decreased fexofenadine AUC by 41% and Cmax by 43%.",consensus set annotator team,326,375
package-insert-section-139.txt,Active ingredient,ketoconazole ,consensus set annotator team,619,631,Active ingredient,fexofenadine ,consensus set annotator team,,690,702,Positive,Qualitative,"However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.",consensus set annotator team,655,686
package-insert-section-139.txt,Active ingredient,erythromycin ,consensus set annotator team,635,647,Active ingredient,fexofenadine ,consensus set annotator team,,690,702,Positive,Qualitative,"However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.",consensus set annotator team,655,686
package-insert-section-139.txt,Active ingredient,erythromycin ,consensus set annotator team,635,647,Active ingredient,fexofenadine ,consensus set annotator team,,580,592,Positive,Qualitative,"However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.",consensus set annotator team,655,686
package-insert-section-139.txt,Active ingredient,Fexofenadine ,consensus set annotator team,730,742,Active ingredient,erythromycin ,consensus set annotator team,,791,803,Negative,Qualitative,Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.,consensus set annotator team,743,780
package-insert-section-139.txt,Active ingredient,Fexofenadine ,consensus set annotator team,730,742,Active ingredient,ketoconazole ,consensus set annotator team,,807,819,Negative,Qualitative,Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.,consensus set annotator team,743,780
package-insert-section-139.txt,Active ingredient,ketoconazole ,consensus set annotator team,1638,1650,Active ingredient,fexofenadine ,consensus set annotator team,,1693,1705,Positive,Qualitative,These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.,consensus set annotator team,1684,1733
package-insert-section-139.txt,Active ingredient,erythromycin ,consensus set annotator team,1654,1666,Active ingredient,fexofenadine ,consensus set annotator team,,1693,1705,Positive,Qualitative,These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.,consensus set annotator team,1684,1733
package-insert-section-14.txt,Active ingredient,sertraline ,consensus set annotator team,66,76,Active ingredient,pimozide ,consensus set annotator team,,49,57,Positive,Quantitative,"In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.)co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG.",consensus set annotator team,146,193
package-insert-section-141.txt,Active ingredient,cimetidine ,consensus set annotator team,251,261,Active ingredient,amlodipine ,consensus set annotator team,,226,236,Negative,Qualitative,"7.2 Cimetidine

Coadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate.",consensus set annotator team,262,296
package-insert-section-141.txt,Active ingredient,magnesium ,consensus set annotator team,594,603,Active ingredient,amlodipine ,consensus set annotator team,,657,667,Negative,Qualitative,"7.4 Magnesium and Aluminum Hydroxide Antacid

Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate.",consensus set annotator team,677,726
package-insert-section-141.txt,Active ingredient,aluminum ,consensus set annotator team,608,616,Active ingredient,amlodipine ,consensus set annotator team,,657,667,Negative,Qualitative,"7.4 Magnesium and Aluminum Hydroxide Antacid

Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate.",consensus set annotator team,677,726
package-insert-section-141.txt,Active ingredient,sildenafil ,consensus set annotator team,792,802,Active ingredient,amlodipine ,consensus set annotator team,,894,904,Negative,Qualitative,"7.5 Sildenafil

A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate.",consensus set annotator team,843,890
package-insert-section-141.txt,Active ingredient,amlodipine ,consensus set annotator team,1117,1127,Active ingredient,atorvastatin ,consensus set annotator team,,1151,1163,Negative,Qualitative,"7.6 Atorvastatin

Coadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.",consensus set annotator team,1176,1244
package-insert-section-141.txt,Active ingredient,amlodipine ,consensus set annotator team,1296,1306,Active ingredient,digoxin ,consensus set annotator team,,1321,1328,Negative,Qualitative,"7.7 Digoxin

Coadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.",consensus set annotator team,1329,1343
package-insert-section-141.txt,Active ingredient,amlodipine ,consensus set annotator team,1473,1483,Active ingredient,ethanol ,consensus set annotator team,,1546,1553,Negative,Qualitative,"7.8 Ethanol (Alcohol)

Single and multiple 10 mg doses of amlodipine besylate had no significant effect on the pharmacokinetics of ethanol.",consensus set annotator team,1497,1518
package-insert-section-141.txt,Active ingredient,amlodipine ,consensus set annotator team,1590,1600,Active ingredient,warfarin ,consensus set annotator team,,1615,1623,Negative,Qualitative,"7.9 Warfarin

Coadministration of amlodipine besylate with warfarin did not change the warfarin prothrombin response time.",consensus set annotator team,1624,1638
package-insert-section-145.txt,Active ingredient,valproate ,consensus set annotator team,73,82,Drug product,Felbatol ,consensus set annotator team,,103,111,Negative,Qualitative,Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol at steady-state.,consensus set annotator team,48,99
package-insert-section-145.txt,Active ingredient,valproate ,consensus set annotator team,157,166,Active ingredient,felbamate ,consensus set annotator team,,236,245,Positive,Qualitative,"Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol (felbamate) plasma concentrations.",consensus set annotator team,170,268
package-insert-section-146.txt,Active ingredient,Felbamate ,consensus set annotator team,370,379,Active ingredient,gestodene ,consensus set annotator team,,424,433,Positive,Quantitative,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.",consensus set annotator team,404,442
package-insert-section-146.txt,Active ingredient,Felbamate ,consensus set annotator team,370,379,Active ingredient,estradiol ,consensus set annotator team,,536,545,Negative,Qualitative,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.",consensus set annotator team,448,524
package-insert-section-147.txt,Drug product,Felbatol ,consensus set annotator team,11,19,Active ingredient,phenytoin ,consensus set annotator team,,56,65,Positive,Quantitative,Phenytoin: Felbatol causes an increase in steady-state phenytoin plasma concentrations.,consensus set annotator team,417,480
package-insert-section-147.txt,Active ingredient,felbamate ,consensus set annotator team,362,371,Active ingredient,phenytoin ,consensus set annotator team,,444,453,Positive,Quantitative,Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 257 micrograms/mL.,consensus set annotator team,417,480
package-insert-section-148.txt,Drug product,Felbatol ,consensus set annotator team,15,23,Active ingredient,carbamazepine ,consensus set annotator team,,63,76,Positive,Qualitative,Carbamazepine: Felbatol causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.,consensus set annotator team,34,98
package-insert-section-148.txt,Drug product,Felbatol ,consensus set annotator team,15,23,Metabolite,carbamazepine epoxide ,consensus set annotator team,carbamazepine ,135,156,Positive,Qualitative,Carbamazepine: Felbatol causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.,consensus set annotator team,106,177
package-insert-section-148.txt,Active ingredient,felbamate ,consensus set annotator team,411,420,Active ingredient,carbamazepine ,consensus set annotator team,,339,352,Positive,Quantitative,"The carbamazepine steady-state Cmin decreased 31% to 51 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.",consensus set annotator team,366,384
package-insert-section-148.txt,Active ingredient,felbamate ,consensus set annotator team,609,618,Metabolite,Carbamazepine epoxide ,consensus set annotator team,carbamazepine ,481,502,Positive,Quantitative,Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.00.3 to 1.60.4 micrograms/mL with the addition of felbamate.,consensus set annotator team,516,548
package-insert-section-149.txt,Drug product,Felbatol ,consensus set annotator team,11,19,Active ingredient,valproate ,consensus set annotator team,,56,65,Positive,Qualitative,Valproate: Felbatol causes an increase in steady-state valproate concentrations.,consensus set annotator team,31,80
package-insert-section-149.txt,Active ingredient,felbamate ,consensus set annotator team,341,350,Active ingredient,valproate ,consensus set annotator team,,398,407,Positive,Quantitative,Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 9625 micrograms/mL.,consensus set annotator team,371,435
package-insert-section-149.txt,Drug product,Felbatol ,consensus set annotator team,881,889,Active ingredient,valproate ,consensus set annotator team,,819,828,Negative,Qualitative,This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol. ,consensus set annotator team,800,843
package-insert-section-15.txt,Active ingredient,sertraline ,consensus set annotator team,98,108,Active ingredient,phenytoin ,consensus set annotator team,,172,181,Negative,Qualitative,Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism.,consensus set annotator team,120,192
package-insert-section-150.txt,Active ingredient,felbamate ,consensus set annotator team,35,44,Active ingredient,phenobarbital ,consensus set annotator team,,50,63,Negative,Qualitative,Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations.,consensus set annotator team,74,121
package-insert-section-150.txt,Active ingredient,felbamate ,consensus set annotator team,359,368,Active ingredient,phenobarbital ,consensus set annotator team,,219,232,Positive,Quantitative,The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.,consensus set annotator team,288,338
package-insert-section-151.txt,Active ingredient,Phenytoin ,consensus set annotator team,11,20,Active ingredient,felbamate ,consensus set annotator team,,83,92,Positive,Quantitative,"Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.",consensus set annotator team,21,68
package-insert-section-151.txt,Active ingredient,phenytoin ,consensus set annotator team,142,151,Drug product,Felbatol ,consensus set annotator team,,232,240,Positive,Quantitative,"Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.",consensus set annotator team,174,228
package-insert-section-152.txt,Active ingredient,carbamazepine ,consensus set annotator team,142,155,Drug product,Felbatol ,consensus set annotator team,,240,248,Positive,Quantitative,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy. ",consensus set annotator team,182,236
package-insert-section-152.txt,Active ingredient,Carbamazepine ,consensus set annotator team,15,28,Drug product,Felbatol ,consensus set annotator team,,84,92,Positive,Quantitative,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy. ",consensus set annotator team,29,80
package-insert-section-155.txt,Active ingredient,ritonavir ,consensus set annotator team,8627,8636,Active ingredient,sildenafil ,consensus set annotator team,,8770,8780,Positive,Quantitative,"Ritonavir and other CYP3A Inhibitors

In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.",consensus set annotator team,8730,8785
package-insert-section-155.txt,Active ingredient,ritonavir ,consensus set annotator team,8627,8636,Active ingredient,sildenafil ,consensus set annotator team,,8820,8830,Positive,Quantitative,"Ritonavir and other CYP3A Inhibitors

In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.",consensus set annotator team,8792,8841
package-insert-section-155.txt,Active ingredient,saquinavir ,consensus set annotator team,9146,9156,Active ingredient,sildenafil ,consensus set annotator team,,9238,9248,Positive,Qualitative,"Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.",consensus set annotator team,9217,9255
package-insert-section-155.txt,Active ingredient,Cimetidine ,consensus set annotator team,9791,9801,Active ingredient,sildenafil ,consensus set annotator team,,9873,9883,Positive,Quantitative,"Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.",consensus set annotator team,9841,9898
package-insert-section-155.txt,Active ingredient,erythromycin ,consensus set annotator team,10033,10045,Active ingredient,sildenafil ,consensus set annotator team,,10136,10146,Positive,Quantitative,"When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).",consensus set annotator team,10119,10169
package-insert-section-155.txt,Active ingredient,saquinavir ,consensus set annotator team,10265,10275,Active ingredient,sildenafil ,consensus set annotator team,,10394,10404,Positive,Quantitative,"In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.",consensus set annotator team,10363,10447
package-insert-section-155.txt,Active ingredient,saquinavir ,consensus set annotator team,10265,10275,Active ingredient,sildenafil ,consensus set annotator team,,10433,10443,Positive,Quantitative,"In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.",consensus set annotator team,10416,10447
package-insert-section-155.txt,Active ingredient,sildenafil ,consensus set annotator team,10714,10724,Active ingredient,bosentan ,consensus set annotator team,,11010,11018,Positive,Quantitative,"Bosentan

In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.",consensus set annotator team,10987,11018
package-insert-section-155.txt,Active ingredient,bosentan ,consensus set annotator team,10758,10766,Active ingredient,sildenafil ,consensus set annotator team,,10938,10948,Positive,Quantitative,"Bosentan

In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.",consensus set annotator team,10922,10953
package-insert-section-155.txt,Active ingredient,bosentan ,consensus set annotator team,10758,10766,Active ingredient,sildenafil ,consensus set annotator team,,10901,10911,Positive,Quantitative,"Bosentan

In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.",consensus set annotator team,10885,10915
package-insert-section-155.txt,Active ingredient,epoprostenol ,consensus set annotator team,11364,11376,Active ingredient,sildenafil ,consensus set annotator team,,11297,11307,Positive,Quantitative,"Epoprostenol

The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.",consensus set annotator team,11405,11455
package-insert-section-155.txt,Active ingredient,sildenafil ,consensus set annotator team,11970,11980,Active ingredient,ritonavir ,consensus set annotator team,,12085,12094,Negative,Qualitative,"In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.",consensus set annotator team,11990,12038
package-insert-section-155.txt,Active ingredient,sildenafil ,consensus set annotator team,11970,11980,Active ingredient,saquinavir ,consensus set annotator team,,12070,12080,Negative,Qualitative,"In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.",consensus set annotator team,11990,12038
package-insert-section-155.txt,Active ingredient,ethinyl estradiol ,consensus set annotator team,12333,12350,Active ingredient,sildenafil ,consensus set annotator team,,12425,12435,Negative,Qualitative,"Oral Contraceptives

Concomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.",consensus set annotator team,12386,12421
package-insert-section-155.txt,Active ingredient,levonorgestrel ,consensus set annotator team,12362,12376,Active ingredient,sildenafil ,consensus set annotator team,,12425,12435,Negative,Qualitative,"Oral Contraceptives

Concomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.",consensus set annotator team,12386,12421
package-insert-section-155.txt,Active ingredient,Sildenafil ,consensus set annotator team,12437,12447,Active ingredient,levonorgestrel ,consensus set annotator team,,12536,12550,Negative,Qualitative,Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).,consensus set annotator team,12448,12482
package-insert-section-155.txt,Active ingredient,Sildenafil ,consensus set annotator team,12437,12447,Active ingredient,ethinyl estradiol ,consensus set annotator team,,12507,12524,Negative,Qualitative,Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).,consensus set annotator team,12448,12482
package-insert-section-155.txt,Active ingredient,sildenafil ,consensus set annotator team,12630,12640,Active ingredient,atorvastatin ,consensus set annotator team,,12727,12739,Negative,Qualitative,"Atorvastatin

Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.",consensus set annotator team,12668,12723
package-insert-section-155.txt,Active ingredient,atorvastatin ,consensus set annotator team,12655,12667,Active ingredient,sildenafil ,consensus set annotator team,,12713,12723,Negative,Qualitative,"Atorvastatin

Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.",consensus set annotator team,12668,12723
package-insert-section-155.txt,Active ingredient,magnesium hydroxide ,consensus set annotator team,12777,12796,Active ingredient,sildenafil ,consensus set annotator team,,12855,12865,Negative,Qualitative,"Antacids

Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.",consensus set annotator team,12817,12851
package-insert-section-155.txt,Active ingredient,aluminum hydroxide ,consensus set annotator team,12797,12815,Active ingredient,sildenafil ,consensus set annotator team,,12855,12865,Negative,Qualitative,"Antacids

Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.",consensus set annotator team,12817,12851
package-insert-section-156.txt,Active ingredient,irbesartan ,consensus set annotator team,160,170,Active ingredient,aliskiren ,consensus set annotator team,,179,188,Positive,Quantitative,Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.,consensus set annotator team,171,202
package-insert-section-156.txt,Active ingredient,atorvastatin ,consensus set annotator team,543,555,Active ingredient,aliskiren ,consensus set annotator team,,592,601,Positive,Quantitative,Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.,consensus set annotator team,576,614
package-insert-section-156.txt,Active ingredient,ketoconazole ,consensus set annotator team,692,704,Active ingredient,aliskiren ,consensus set annotator team,,710,719,Positive,Quantitative,Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.,consensus set annotator team,747,789
package-insert-section-156.txt,Active ingredient,itraconazole ,consensus set annotator team,940,952,Active ingredient,aliskiren ,consensus set annotator team,,965,974,Positive,Quantitative,Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.,consensus set annotator team,975,1055
package-insert-section-156.txt,Active ingredient,cyclosporine ,consensus set annotator team,1190,1202,Active ingredient,aliskiren ,consensus set annotator team,,1214,1223,Positive,Quantitative,Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.,consensus set annotator team,1253,1305
package-insert-section-156.txt,Active ingredient,verapamil ,consensus set annotator team,1430,1439,Active ingredient,aliskiren ,consensus set annotator team,,1452,1461,Positive,Quantitative,Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.,consensus set annotator team,1491,1522
package-insert-section-156.txt,Active ingredient,lovastatin ,consensus set annotator team,1648,1658,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,atenolol ,consensus set annotator team,1660,1668,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,warfarin ,consensus set annotator team,1670,1678,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,furosemide ,consensus set annotator team,1680,1690,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,digoxin ,consensus set annotator team,1692,1699,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,celecoxib ,consensus set annotator team,1701,1710,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,hydrochlorothiazide ,consensus set annotator team,1712,1731,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,ramipril ,consensus set annotator team,1733,1741,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,valsartan ,consensus set annotator team,1743,1752,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,metformin ,consensus set annotator team,1754,1763,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,amlodipine ,consensus set annotator team,1768,1778,Active ingredient,aliskiren ,consensus set annotator team,,1833,1842,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.",consensus set annotator team,1779,1851
package-insert-section-156.txt,Active ingredient,aliskiren ,consensus set annotator team,2024,2033,Active ingredient,furosemide ,consensus set annotator team,,2058,2068,Positive,Quantitative,"Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.",consensus set annotator team,2074,2133
package-insert-section-156.txt,Active ingredient,aliskiren ,consensus set annotator team,2306,2315,Active ingredient,ramipril ,consensus set annotator team,,2459,2467,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.",consensus set annotator team,2316,2365
package-insert-section-156.txt,Active ingredient,aliskiren ,consensus set annotator team,2306,2315,Active ingredient,hydrochlorothiazide ,consensus set annotator team,,2471,2490,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.",consensus set annotator team,2316,2365
package-insert-section-156.txt,Active ingredient,aliskiren ,consensus set annotator team,2306,2315,Active ingredient,lovastatin ,consensus set annotator team,,2369,2379,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.",consensus set annotator team,2316,2365
package-insert-section-156.txt,Active ingredient,aliskiren ,consensus set annotator team,2306,2315,Active ingredient,digoxin ,consensus set annotator team,,2381,2388,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.",consensus set annotator team,2316,2365
package-insert-section-156.txt,Active ingredient,aliskiren ,consensus set annotator team,2306,2315,Active ingredient,valsartan ,consensus set annotator team,,2390,2399,Negative,Qualitative,"Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.",consensus set annotator team,2316,2365
package-insert-section-158.txt,Active ingredient,fluvoxamine ,consensus set annotator team,348,359,Active ingredient,mexiletine ,consensus set annotator team,,282,292,Positive,Quantitative,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.",consensus set annotator team,297,313
package-insert-section-158.txt,Active ingredient,propafenone ,consensus set annotator team,486,497,Active ingredient,mexiletine ,consensus set annotator team,,528,538,Negative,Qualitative,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.",consensus set annotator team,498,524
package-insert-section-158.txt,Active ingredient,propafenone ,consensus set annotator team,486,497,Active ingredient,mexiletine ,consensus set annotator team,,613,623,Positive,Quantitative,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.",consensus set annotator team,600,685
package-insert-section-158.txt,Active ingredient,mexiletine ,consensus set annotator team,891,901,Active ingredient,propafenone ,consensus set annotator team,,816,827,Negative,Qualitative,"In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.",consensus set annotator team,796,843
package-insert-section-159.txt,Active ingredient,Mexiletine ,consensus set annotator team,0,10,Active ingredient,digoxin ,consensus set annotator team,,32,39,Negative,Qualitative,"Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.",consensus set annotator team,11,46
package-insert-section-159.txt,Active ingredient,magnesium ,consensus set annotator team,51,60,Active ingredient,digoxin ,consensus set annotator team,,205,212,Positive,Qualitative,"Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.",consensus set annotator team,176,219
package-insert-section-159.txt,Active ingredient,aluminum ,consensus set annotator team,61,69,Active ingredient,digoxin ,consensus set annotator team,,205,212,Positive,Qualitative,"Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.",consensus set annotator team,176,219
package-insert-section-16.txt,Active ingredient,sertraline ,consensus set annotator team,231,241,Active ingredient,cisapride ,consensus set annotator team,,315,324,Negative,Qualitative,"The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.",consensus set annotator team,242,280
package-insert-section-16.txt,Active ingredient,sertraline ,consensus set annotator team,231,241,Active ingredient,terfenadine ,consensus set annotator team,,284,295,Negative,Qualitative,"The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.",consensus set annotator team,242,280
package-insert-section-16.txt,Active ingredient,sertraline ,consensus set annotator team,231,241,Active ingredient,carbamazepine ,consensus set annotator team,,297,310,Negative,Qualitative,"The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.",consensus set annotator team,242,280
package-insert-section-16.txt,Active ingredient,sertraline ,consensus set annotator team,514,524,Active ingredient,cisapride ,consensus set annotator team,,490,499,Positive,Quantitative,Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.)induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).,consensus set annotator team,539,624
package-insert-section-161.txt,Active ingredient,nelfinavir ,consensus set annotator team,20,30,Active ingredient,azithromycin ,consensus set annotator team,,74,86,Positive,Qualitative,Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations.,consensus set annotator team,99,142
package-insert-section-163.txt,Active ingredient,acyclovir ,consensus set annotator team,102,111,Active ingredient,meperidine ,consensus set annotator team,,36,46,Positive,Qualitative,"Acyclovir

Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.",consensus set annotator team,11,98
package-insert-section-163.txt,Active ingredient,acyclovir ,consensus set annotator team,102,111,Metabolite,normeperidine ,consensus set annotator team,meperidine ,67,80,Positive,Qualitative,"Acyclovir

Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.",consensus set annotator team,11,98
package-insert-section-164.txt,Active ingredient,Cimetidine ,consensus set annotator team,12,22,Active ingredient,meperidine ,consensus set annotator team,,75,85,Positive,Qualitative,"Cimetidine

Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.",consensus set annotator team,23,71
package-insert-section-164.txt,Active ingredient,Cimetidine ,consensus set annotator team,12,22,Metabolite,normeperidine ,consensus set annotator team,meperidine ,128,141,Positive,Qualitative,"Cimetidine

Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.",consensus set annotator team,23,71
package-insert-section-166.txt,Active ingredient,Penicillin ,consensus set annotator team,0,10,Active ingredient,methotrexate ,consensus set annotator team,,46,58,Positive,Qualitative,Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate.,consensus set annotator team,60,90
package-insert-section-168.txt,Active ingredient,Clonazepam ,consensus set annotator team,61,71,Active ingredient,carbamazepine ,consensus set annotator team,,132,145,Negative,Qualitative,"Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.",consensus set annotator team,72,117
package-insert-section-168.txt,Active ingredient,Clonazepam ,consensus set annotator team,61,71,Active ingredient,carbamazepine ,consensus set annotator team,,132,145,Negative,Qualitative,"Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.",consensus set annotator team,72,117
package-insert-section-168.txt,Active ingredient,Clonazepam ,consensus set annotator team,61,71,Active ingredient,phenytoin ,consensus set annotator team,,121,130,Negative,Qualitative,"Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.",consensus set annotator team,72,117
package-insert-section-168.txt,Active ingredient,Clonazepam ,consensus set annotator team,61,71,Active ingredient,phenobarbital ,consensus set annotator team,,149,162,Negative,Qualitative,"Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.",consensus set annotator team,72,117
package-insert-section-17.txt,Active ingredient,sertraline ,consensus set annotator team,70,80,Active ingredient,tolbutamide ,consensus set annotator team,,220,231,Positive,Quantitative,"In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.",consensus set annotator team,173,216
package-insert-section-170.txt,Active ingredient,cholestyramine ,consensus set annotator team,666,680,Active ingredient,hydrochlorothiazide ,consensus set annotator team,,711,730,Positive,Quantitative,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.",consensus set annotator team,735,808
package-insert-section-170.txt,Active ingredient,colestipol ,consensus set annotator team,684,694,Active ingredient,hydrochlorothiazide ,consensus set annotator team,,711,730,Positive,Quantitative,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.",consensus set annotator team,735,808
package-insert-section-170.txt,Drug product,AVALIDE ,consensus set annotator team,1403,1410,Active ingredient,lithium ,consensus set annotator team,,1264,1271,Positive,Qualitative,Refer to the package insert for lithium preparations before use of such preparations with AVALIDE.,consensus set annotator team,1234,1271
package-insert-section-171.txt,Active ingredient,hydrochlorothiazide ,consensus set annotator team,9191,9210,Active ingredient,irbesartan ,consensus set annotator team,,9125,9135,Negative,Qualitative,The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.,consensus set annotator team,9101,9153
package-insert-section-171.txt,Active ingredient,nifedipine ,consensus set annotator team,8604,8614,Active ingredient,irbesartan ,consensus set annotator team,,8655,8665,Negative,Qualitative,Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.,consensus set annotator team,8638,8682
package-insert-section-171.txt,Active ingredient,hydrochlorothiazide ,consensus set annotator team,8618,8637,Active ingredient,irbesartan ,consensus set annotator team,,8655,8665,Negative,Qualitative,Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.,consensus set annotator team,8638,8682
package-insert-section-171.txt,Active ingredient,irbesartan ,consensus set annotator team,8959,8969,Active ingredient,warfarin ,consensus set annotator team,,8916,8924,Negative,Qualitative,"In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.",consensus set annotator team,8996,9088
package-insert-section-171.txt,Active ingredient,irbesartan ,consensus set annotator team,8959,8969,Active ingredient,digoxin ,consensus set annotator team,,8950,8957,Negative,Qualitative,"In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.",consensus set annotator team,8996,9088
package-insert-section-171.txt,Active ingredient,nifedipine ,consensus set annotator team,9177,9187,Active ingredient,irbesartan ,consensus set annotator team,,9125,9135,Negative,Qualitative,The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.,consensus set annotator team,9101,9153
package-insert-section-172.txt,Active ingredient,clarithromycin ,consensus set annotator team,816,830,Drug product,LIPITOR ,consensus set annotator team,,797,804,Positive,Qualitative,Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,730,761
package-insert-section-172.txt,Active ingredient,clarithromycin ,consensus set annotator team,816,830,Active ingredient,Atorvastatin ,consensus set annotator team,,717,729,Positive,Qualitative,Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,730,761
package-insert-section-172.txt,Active ingredient,ritonavir ,consensus set annotator team,1260,1269,Drug product,LIPITOR ,consensus set annotator team,,1241,1248,Positive,Qualitative,Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,1174,1205
package-insert-section-172.txt,Active ingredient,ritonavir ,consensus set annotator team,1260,1269,Active ingredient,Atorvastatin ,consensus set annotator team,,1161,1173,Positive,Qualitative,Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,1174,1205
package-insert-section-172.txt,Active ingredient,ritonavir ,consensus set annotator team,1344,1353,Active ingredient,Atorvastatin ,consensus set annotator team,,1161,1173,Positive,Qualitative,Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,1174,1205
package-insert-section-172.txt,Active ingredient,saquinavir ,consensus set annotator team,1275,1285,Drug product,LIPITOR ,consensus set annotator team,,1241,1248,Positive,Qualitative,Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,1174,1205
package-insert-section-172.txt,Active ingredient,saquinavir ,consensus set annotator team,1275,1285,Active ingredient,Atorvastatin ,consensus set annotator team,,1161,1173,Positive,Qualitative,Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,1174,1205
package-insert-section-172.txt,Active ingredient,lopinavir ,consensus set annotator team,1329,1338,Drug product,LIPITOR ,consensus set annotator team,,1241,1248,Positive,Qualitative,Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,1174,1205
package-insert-section-172.txt,Active ingredient,lopinavir ,consensus set annotator team,1329,1338,Active ingredient,Atorvastatin ,consensus set annotator team,,1161,1173,Positive,Qualitative,Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,1174,1205
package-insert-section-172.txt,Active ingredient,itraconazole ,consensus set annotator team,1778,1790,Active ingredient,Atorvastatin ,consensus set annotator team,,1680,1692,Positive,Qualitative,Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].,consensus set annotator team,1693,1724
package-insert-section-172.txt,Active ingredient,cyclosporine ,consensus set annotator team,2537,2549,Active ingredient,Atorvastatin ,consensus set annotator team,,2439,2451,Positive,Qualitative,Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].,consensus set annotator team,2452,2483
package-insert-section-172.txt,Active ingredient,efavirenz ,consensus set annotator team,2947,2956,Drug product,LIPITOR ,consensus set annotator team,,2895,2902,Positive,Qualitative,"7.4 Rifampin or other Inducers of Cytochrome P450 3A4

Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.",consensus set annotator team,2968,3024
package-insert-section-172.txt,Active ingredient,rifampin ,consensus set annotator team,2958,2966,Drug product,LIPITOR ,consensus set annotator team,,2895,2902,Positive,Qualitative,"7.4 Rifampin or other Inducers of Cytochrome P450 3A4

Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.",consensus set annotator team,2968,3024
package-insert-section-172.txt,Active ingredient,rifampin ,consensus set annotator team,3226,3234,Active ingredient,atorvastatin ,consensus set annotator team,,3287,3299,Positive,Qualitative,"Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.",consensus set annotator team,3262,3321
package-insert-section-172.txt,Drug product,LIPITOR ,consensus set annotator team,3360,3367,Active ingredient,digoxin ,consensus set annotator team,,3372,3379,Positive,Quantitative,"7.5 Digoxin

When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.",consensus set annotator team,3429,3474
package-insert-section-172.txt,Drug product,LIPITOR ,consensus set annotator team,3360,3367,Active ingredient,digoxin ,consensus set annotator team,,3421,3428,Positive,Quantitative,"7.5 Digoxin

When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.",consensus set annotator team,3429,3474
package-insert-section-172.txt,Drug product,LIPITOR ,consensus set annotator team,3582,3589,Active ingredient,norethindrone ,consensus set annotator team,,3641,3654,Positive,Qualitative,"7.6 Oral Contraceptives

Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].",consensus set annotator team,3616,3629
package-insert-section-172.txt,Drug product,LIPITOR ,consensus set annotator team,3582,3589,Active ingredient,ethinyl estradiol ,consensus set annotator team,,3659,3676,Positive,Qualitative,"7.6 Oral Contraceptives

Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].",consensus set annotator team,3616,3629
package-insert-section-174.txt,Active ingredient,rifampin ,consensus set annotator team,140,148,Active ingredient,tacrolimus ,consensus set annotator team,,61,71,Positive,Quantitative,"In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (146% vs. 73%) was observed with concomitant rifampin administration (600 mg).",consensus set annotator team,49,109
package-insert-section-174.txt,Active ingredient,rifampin ,consensus set annotator team,307,315,Active ingredient,tacrolimus ,consensus set annotator team,,223,233,Positive,Quantitative,"In addition, there was a significant increase in tacrolimus clearance (0.0360.008 L/hr/kg vs. 0.0530.010 L/hr/kg) with concomitant rifampin administration.",consensus set annotator team,211,288
package-insert-section-175.txt,Active ingredient,nelfinavir ,consensus set annotator team,369,379,Active ingredient,tacrolimus ,consensus set annotator team,,353,363,Positive,Qualitative,"Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.",consensus set annotator team,380,410
package-insert-section-175.txt,Active ingredient,Tacrolimus ,consensus set annotator team,747,757,Active ingredient,phenytoin ,consensus set annotator team,,812,821,Positive,Qualitative,"Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration.",consensus set annotator team,758,855
package-insert-section-177.txt,Active ingredient,cimetidine ,consensus set annotator team,334,344,Active ingredient,diazepam ,consensus set annotator team,,226,234,Positive,Qualitative,"At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.",consensus set annotator team,192,222
package-insert-section-177.txt,Active ingredient,ketoconazole ,consensus set annotator team,346,358,Active ingredient,diazepam ,consensus set annotator team,,226,234,Positive,Qualitative,"At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.",consensus set annotator team,192,222
package-insert-section-177.txt,Active ingredient,fluvoxamine ,consensus set annotator team,360,371,Active ingredient,diazepam ,consensus set annotator team,,226,234,Positive,Qualitative,"At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.",consensus set annotator team,192,222
package-insert-section-177.txt,Active ingredient,fluoxetine ,consensus set annotator team,373,383,Active ingredient,diazepam ,consensus set annotator team,,226,234,Positive,Qualitative,"At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.",consensus set annotator team,192,222
package-insert-section-177.txt,Active ingredient,omeprazole ,consensus set annotator team,389,399,Active ingredient,diazepam ,consensus set annotator team,,226,234,Positive,Qualitative,"At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.",consensus set annotator team,192,222
package-insert-section-179.txt,Active ingredient,Isoniazid ,consensus set annotator team,15,24,Active ingredient,carbamazepine ,consensus set annotator team,,60,73,Positive,Qualitative,"Carbamazepine

Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels.",consensus set annotator team,78,103
package-insert-section-181.txt,Active ingredient,erythromycin ,consensus set annotator team,257,269,Active ingredient,verapamil ,consensus set annotator team,,320,329,Positive,Qualitative,"Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.",consensus set annotator team,282,316
package-insert-section-181.txt,Active ingredient,ritonavir ,consensus set annotator team,271,280,Active ingredient,verapamil ,consensus set annotator team,,320,329,Positive,Qualitative,"Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.",consensus set annotator team,282,316
package-insert-section-181.txt,Active ingredient,rifampin ,consensus set annotator team,527,535,Active ingredient,verapamil ,consensus set annotator team,,580,589,Positive,Qualitative,"Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.",consensus set annotator team,551,576
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,2278,2287,Active ingredient,metoprolol ,consensus set annotator team,,2171,2181,Positive,Qualitative,A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.,consensus set annotator team,2159,2207
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,2278,2287,Active ingredient,propranolol ,consensus set annotator team,,2186,2197,Positive,Qualitative,A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.,consensus set annotator team,2159,2207
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,2529,2538,Active ingredient,digoxin ,consensus set annotator team,,2568,2575,Positive,Quantitative,"Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.",consensus set annotator team,2553,2595
package-insert-section-181.txt,Active ingredient,Verapamil ,consensus set annotator team,2778,2787,Active ingredient,digitoxin ,consensus set annotator team,,2848,2857,Positive,Quantitative,"Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.",consensus set annotator team,2792,2871
package-insert-section-181.txt,Active ingredient,Verapamil ,consensus set annotator team,3285,3294,Active ingredient,ethanol ,consensus set annotator team,,3335,3342,Positive,Qualitative,"7.5 Alcohol

Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.",consensus set annotator team,3327,3405
package-insert-section-181.txt,Active ingredient,Verapamil ,consensus set annotator team,3930,3939,Active ingredient,doxorubicin ,consensus set annotator team,,3953,3964,Positive,Qualitative,"7.8 Antineoplastic Agents

Verapamil can increase doxorubicin levels.",consensus set annotator team,3944,3971
package-insert-section-181.txt,Active ingredient,cyclophosphamide ,consensus set annotator team,4023,4039,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Drug product,oncovin ,consensus set annotator team,4041,4048,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Active ingredient,oncovin ,consensus set annotator team,4041,4048,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Active ingredient,procarbazine ,consensus set annotator team,4050,4062,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Active ingredient,prednisone ,consensus set annotator team,4064,4074,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Active ingredient,vindesine ,consensus set annotator team,4090,4099,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Drug product,adriamycin ,consensus set annotator team,4101,4111,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Active ingredient,adriamycin ,consensus set annotator team,4101,4111,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Active ingredient,cisplatin ,consensus set annotator team,4113,4122,Active ingredient,verapamil ,consensus set annotator team,,3991,4000,Positive,Qualitative,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",consensus set annotator team,3977,4015
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,4186,4195,Active ingredient,paclitaxel ,consensus set annotator team,,4226,4236,Positive,Qualitative,Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.,consensus set annotator team,4196,4222
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,4778,4787,Active ingredient,quinidine ,consensus set annotator team,,4754,4763,Positive,Qualitative,There has been a report of increased quinidine levels during verapamil therapy.,consensus set annotator team,4744,4770
package-insert-section-181.txt,Active ingredient,Verapamil ,consensus set annotator team,6125,6134,Active ingredient,carbamazepine ,consensus set annotator team,,6156,6169,Positive,Qualitative,"7.14 Carbamazepine

Verapamil therapy may increase carbamazepine concentrations during combined therapy.",consensus set annotator team,6147,6184
package-insert-section-181.txt,Active ingredient,Verapamil ,consensus set annotator team,6323,6332,Active ingredient,cyclosporine ,consensus set annotator team,,6370,6382,Positive,Qualitative,"7.15 Cyclosporine

Verapamil therapy may increase serum levels of cyclosporine.",consensus set annotator team,6341,6366
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,6500,6509,Active ingredient,lithium ,consensus set annotator team,,6510,6517,Negative,Qualitative,"7.16 Lithium

Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.",consensus set annotator team,6554,6586
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,6500,6509,Active ingredient,lithium ,consensus set annotator team,,6572,6579,Positive,Qualitative,"7.16 Lithium

Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.",consensus set annotator team,6554,6586
package-insert-section-181.txt,Active ingredient,verapamil ,consensus set annotator team,6613,6622,Active ingredient,lithium ,consensus set annotator team,,6666,6673,Positive,Qualitative,"However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.",consensus set annotator team,6648,6680
package-insert-section-181.txt,Active ingredient,Phenobarbital ,consensus set annotator team,7467,7480,Active ingredient,verapamil ,consensus set annotator team,,7502,7511,Positive,Qualitative,"7.19 Phenobarbital

Phenobarbital therapy may increase verapamil clearance.",consensus set annotator team,7489,7521
package-insert-section-181.txt,Active ingredient,rifampin ,consensus set annotator team,7552,7560,Active ingredient,verapamil ,consensus set annotator team,,7586,7595,Positive,Qualitative,"7.20 Rifampin

Therapy with rifampin may markedly reduce oral verapamil bioavailability.",consensus set annotator team,7574,7611
package-insert-section-181.txt,Active ingredient,Verapamil ,consensus set annotator team,7633,7642,Active ingredient,theophylline ,consensus set annotator team,,7703,7715,Positive,Qualitative,"7.21 Theophylline

Verapamil may inhibit the clearance and increase the plasma levels of theophylline.",consensus set annotator team,7673,7699
package-insert-section-181.txt,Active ingredient,cimetidine ,consensus set annotator team,7759,7769,Active ingredient,verapamil ,consensus set annotator team,,7933,7942,Positive,Qualitative,"7.22 Cimetidine

The interaction between cimetidine and chronically administered verapamil has not been studied.",consensus set annotator team,7920,7974
package-insert-section-181.txt,Active ingredient,cimetidine ,consensus set annotator team,7759,7769,Active ingredient,verapamil ,consensus set annotator team,,7933,7942,Negative,Qualitative,"7.22 Cimetidine

The interaction between cimetidine and chronically administered verapamil has not been studied.",consensus set annotator team,7920,7974
package-insert-section-183.txt,Active ingredient,Lansoprazole ,consensus set annotator team,162,174,Active ingredient,atazanavir ,consensus set annotator team,,310,320,Positive,Qualitative,"Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.",consensus set annotator team,243,279
package-insert-section-183.txt,Active ingredient,lansoprazole ,consensus set annotator team,672,684,Active ingredient,ketoconazole ,consensus set annotator team,,890,902,Positive,Qualitative,"[See Clinical Pharmacology (12.5)]

It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).",consensus set annotator team,725,758
package-insert-section-183.txt,Active ingredient,lansoprazole ,consensus set annotator team,672,684,Active ingredient,iron ,consensus set annotator team,,878,882,Positive,Qualitative,"[See Clinical Pharmacology (12.5)]

It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).",consensus set annotator team,725,758
package-insert-section-183.txt,Active ingredient,lansoprazole ,consensus set annotator team,672,684,Active ingredient,ampicillin ,consensus set annotator team,,850,860,Positive,Qualitative,"[See Clinical Pharmacology (12.5)]

It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).",consensus set annotator team,725,758
package-insert-section-183.txt,Active ingredient,lansoprazole ,consensus set annotator team,672,684,Active ingredient,digoxin ,consensus set annotator team,,869,876,Positive,Qualitative,"[See Clinical Pharmacology (12.5)]

It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).",consensus set annotator team,725,758
package-insert-section-183.txt,Active ingredient,lansoprazole ,consensus set annotator team,1038,1050,Active ingredient,warfarin ,consensus set annotator team,,1128,1136,Negative,Qualitative,"[See Clinical Pharmacology (12.5)]

Warfarin

In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).",consensus set annotator team,1089,1124
package-insert-section-183.txt,Active ingredient,lansoprazole ,consensus set annotator team,1603,1615,Active ingredient,tacrolimus ,consensus set annotator team,,1620,1630,Positive,Qualitative,"[See Clinical Pharmacology (12.5)]

Tacrolimus

Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.",consensus set annotator team,1631,1662
package-insert-section-183.txt,Active ingredient,lansoprazole ,consensus set annotator team,1882,1894,Active ingredient,theophylline ,consensus set annotator team,,1824,1836,Positive,Quantitative,"Theophylline

A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.",consensus set annotator team,1789,1820
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14590,14602,Active ingredient,digoxin ,consensus set annotator team,,14768,14775,Positive,Qualitative,"12.5 Drug-Drug Interactions

It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).",consensus set annotator team,14603,14636
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14590,14602,Active ingredient,iron ,consensus set annotator team,,14756,14760,Positive,Qualitative,"12.5 Drug-Drug Interactions

It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).",consensus set annotator team,14603,14636
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14590,14602,Active ingredient,ketoconazole ,consensus set annotator team,,14723,14735,Positive,Qualitative,"12.5 Drug-Drug Interactions

It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).",consensus set annotator team,14603,14636
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14590,14602,Active ingredient,ampicillin ,consensus set annotator team,,14737,14747,Positive,Qualitative,"12.5 Drug-Drug Interactions

It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).",consensus set annotator team,14603,14636
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,diazepam ,consensus set annotator team,,15134,15142,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,diazepam ,consensus set annotator team,,15134,15142,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,prednisone ,consensus set annotator team,,15122,15132,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,prednisone ,consensus set annotator team,,15122,15132,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,clarithromycin ,consensus set annotator team,,15147,15161,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,clarithromycin ,consensus set annotator team,,15147,15161,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,antipyrine ,consensus set annotator team,,15061,15071,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,antipyrine ,consensus set annotator team,,15061,15071,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,propranolol ,consensus set annotator team,,15109,15120,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,propranolol ,consensus set annotator team,,15109,15120,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,ibuprofen ,consensus set annotator team,,15087,15096,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,ibuprofen ,consensus set annotator team,,15087,15096,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,phenytoin ,consensus set annotator team,,15098,15107,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,phenytoin ,consensus set annotator team,,15098,15107,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,warfarin ,consensus set annotator team,,15051,15059,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,warfarin ,consensus set annotator team,,15051,15059,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,14920,14932,Active ingredient,indomethacin ,consensus set annotator team,,15073,15085,Negative,Qualitative,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.",consensus set annotator team,14933,14982
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,15419,15431,Active ingredient,atazanavir ,consensus set annotator team,,15539,15549,Positive,Qualitative,"Atazanavir: Lansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion.lansoprazole delayed-release capsules substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.",consensus set annotator team,15457,15508
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,15870,15882,Active ingredient,theophylline ,consensus set annotator team,,16018,16030,Positive,Quantitative,"Theophylline: When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.",consensus set annotator team,15975,16014
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,16566,16578,Active ingredient,warfarin ,consensus set annotator team,,16466,16474,Negative,Qualitative,"However, there have been reports of increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including lansoprazole delayed-release capsules, and warfarin concomitantly.",consensus set annotator team,16434,16521
package-insert-section-184.txt,Active ingredient,naproxen ,consensus set annotator team,17280,17288,Active ingredient,methotrexate ,consensus set annotator team,,17403,17415,Negative,Qualitative,"Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",consensus set annotator team,17362,17399
package-insert-section-184.txt,Active ingredient,naproxen ,consensus set annotator team,17280,17288,Metabolite,7-hydroxymethotrexate ,consensus set annotator team,methotrexate ,17420,17441,Negative,Qualitative,"Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",consensus set annotator team,17362,17399
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,17312,17324,Active ingredient,methotrexate ,consensus set annotator team,,17403,17415,Negative,Qualitative,"Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",consensus set annotator team,17362,17399
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,17312,17324,Active ingredient,methotrexate ,consensus set annotator team,,17224,17236,Negative,Qualitative,"Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",consensus set annotator team,17362,17399
package-insert-section-184.txt,Active ingredient,lansoprazole ,consensus set annotator team,17312,17324,Metabolite,7-hydroxymethotrexate ,consensus set annotator team,methotrexate ,17420,17441,Negative,Qualitative,"Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",consensus set annotator team,17362,17399
package-insert-section-184.txt,Active ingredient,Lansoprazole ,consensus set annotator team,17581,17593,Active ingredient,amoxicillin ,consensus set annotator team,,17690,17701,Negative,Qualitative,Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.,consensus set annotator team,17647,17684
package-insert-section-184.txt,Active ingredient,sucralfate ,consensus set annotator team,17871,17881,Active ingredient,lansoprazole ,consensus set annotator team,,17759,17771,Positive,Quantitative,"Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.",consensus set annotator team,17890,17995
package-insert-section-184.txt,Active ingredient,sucralfate ,consensus set annotator team,17871,17881,Active ingredient,omeprazole ,consensus set annotator team,,17807,17817,Positive,Quantitative,"Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.",consensus set annotator team,17890,17995
package-insert-section-185.txt,Active ingredient,simvastatin ,consensus set annotator team,2157,2168,Active ingredient,digoxin ,consensus set annotator team,,2144,2151,Positive,Qualitative,"7.5 Digoxin

In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.",consensus set annotator team,2183,2225
package-insert-section-186.txt,Active ingredient,cyclosporine ,consensus set annotator team,3444,3456,Active ingredient,simvastatin ,consensus set annotator team,,3528,3539,Positive,Qualitative,"Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.",consensus set annotator team,3475,3491
package-insert-section-186.txt,Active ingredient,simvastatin ,consensus set annotator team,3928,3939,Active ingredient,erythromycin ,consensus set annotator team,,4065,4077,Negative,Qualitative,"In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.",consensus set annotator team,3958,3989
package-insert-section-186.txt,Active ingredient,simvastatin ,consensus set annotator team,3928,3939,Active ingredient,erythromycin ,consensus set annotator team,,4065,4077,Negative,Quantitative,"In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.",consensus set annotator team,3962,3989
package-insert-section-186.txt,Active ingredient,simvastatin ,consensus set annotator team,3928,3939,Active ingredient,midazolam ,consensus set annotator team,,4051,4060,Negative,Quantitative,"In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.",consensus set annotator team,3962,3989
package-insert-section-186.txt,Active ingredient,simvastatin ,consensus set annotator team,4261,4272,Active ingredient,digoxin ,consensus set annotator team,,4363,4370,Positive,Quantitative,Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.,consensus set annotator team,4311,4439
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,466,473,Active ingredient,repaglinide ,consensus set annotator team,,597,608,Positive,Qualitative,"Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).",consensus set annotator team,438,460
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,466,473,Active ingredient,paclitaxel ,consensus set annotator team,,585,595,Positive,Qualitative,"Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).",consensus set annotator team,438,460
package-insert-section-187.txt,Active ingredient,atazanavir ,consensus set annotator team,2403,2413,Active ingredient,dapsone ,consensus set annotator team,,2453,2460,Negative,Qualitative,"Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.",consensus set annotator team,2328,2385
package-insert-section-187.txt,Active ingredient,atazanavir ,consensus set annotator team,2403,2413,Active ingredient,trimethoprim ,consensus set annotator team,,2462,2474,Negative,Qualitative,"Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.",consensus set annotator team,2328,2385
package-insert-section-187.txt,Active ingredient,atazanavir ,consensus set annotator team,2403,2413,Active ingredient,pravastatin ,consensus set annotator team,,2440,2451,Negative,Qualitative,"Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.",consensus set annotator team,2328,2385
package-insert-section-187.txt,Active ingredient,atazanavir ,consensus set annotator team,2403,2413,Active ingredient,azithromycin ,consensus set annotator team,,2493,2505,Negative,Qualitative,"Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.",consensus set annotator team,2328,2385
package-insert-section-187.txt,Active ingredient,atazanavir ,consensus set annotator team,2403,2413,Active ingredient,sulfamethoxazole ,consensus set annotator team,,2475,2491,Negative,Qualitative,"Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.",consensus set annotator team,2328,2385
package-insert-section-187.txt,Active ingredient,atazanavir ,consensus set annotator team,2403,2413,Active ingredient,erythromycin ,consensus set annotator team,,2510,2522,Negative,Qualitative,"Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.",consensus set annotator team,2328,2385
package-insert-section-187.txt,Active ingredient,atazanavir ,consensus set annotator team,2403,2413,Active ingredient,fluvastatin ,consensus set annotator team,,2427,2438,Negative,Qualitative,"Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.",consensus set annotator team,2328,2385
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2524,2531,Active ingredient,desipramine ,consensus set annotator team,,2596,2607,Negative,Qualitative,"REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).",consensus set annotator team,2532,2549
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2524,2531,Active ingredient,desipramine ,consensus set annotator team,,2596,2607,Negative,Qualitative,"REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).",consensus set annotator team,2532,2549
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2524,2531,Active ingredient,nortriptyline ,consensus set annotator team,,2581,2594,Negative,Qualitative,"REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).",consensus set annotator team,2532,2549
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2524,2531,Active ingredient,nortriptyline ,consensus set annotator team,,2581,2594,Negative,Qualitative,"REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).",consensus set annotator team,2532,2549
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2524,2531,Active ingredient,metoprolol ,consensus set annotator team,,2609,2619,Negative,Qualitative,"REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).",consensus set annotator team,2532,2549
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2524,2531,Active ingredient,metoprolol ,consensus set annotator team,,2609,2619,Negative,Qualitative,"REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).",consensus set annotator team,2532,2549
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2699,2706,Active ingredient,methadone ,consensus set annotator team,,2731,2740,Negative,Qualitative,"Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.",consensus set annotator team,2636,2693
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2699,2706,Active ingredient,methadone ,consensus set annotator team,,2731,2740,Negative,Qualitative,"Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.",consensus set annotator team,2636,2693
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2699,2706,Active ingredient,acetaminophen ,consensus set annotator team,,2755,2768,Negative,Qualitative,"Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.",consensus set annotator team,2636,2693
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2699,2706,Active ingredient,fluconazole ,consensus set annotator team,,2742,2753,Negative,Qualitative,"Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.",consensus set annotator team,2636,2693
package-insert-section-187.txt,Drug product,REYATAZ ,consensus set annotator team,2699,2706,Active ingredient,atenolol ,consensus set annotator team,,2773,2781,Negative,Qualitative,"Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.",consensus set annotator team,2636,2693
package-insert-section-188.txt,Active ingredient,atazanavir ,consensus set annotator team,1469,1479,Active ingredient,diltiazem ,consensus set annotator team,,1502,1511,Positive,Quantitative,"In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval.",consensus set annotator team,1550,1657
package-insert-section-188.txt,Active ingredient,atazanavir ,consensus set annotator team,1694,1704,Active ingredient,atenolol ,consensus set annotator team,,1727,1735,Negative,Qualitative,"In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval.",consensus set annotator team,1764,1794
package-insert-section-19.txt,Active ingredient,sertraline ,consensus set annotator team,70,80,Active ingredient,digoxin ,consensus set annotator team,,158,165,Negative,Qualitative,"In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.",consensus set annotator team,137,172
package-insert-section-191.txt,Active ingredient,fluvastatin ,consensus set annotator team,45,56,Active ingredient,itraconazole ,consensus set annotator team,,69,81,Negative,Qualitative,"Itraconazole:

Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.",consensus set annotator team,106,163
package-insert-section-191.txt,Active ingredient,itraconazole ,consensus set annotator team,69,81,Active ingredient,fluvastatin ,consensus set annotator team,,45,56,Negative,Qualitative,"Itraconazole:

Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.",consensus set annotator team,106,163
package-insert-section-192.txt,Active ingredient,Erythromycin ,consensus set annotator team,15,27,Active ingredient,fluvastatin ,consensus set annotator team,,95,106,Negative,Qualitative,"Erythromycin:

Erythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily).",consensus set annotator team,50,91
package-insert-section-194.txt,Active ingredient,paroxetine ,consensus set annotator team,103,113,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,ritonavir ,consensus set annotator team,115,124,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,ritonavir ,consensus set annotator team,172,181,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,sertraline ,consensus set annotator team,126,136,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,ketoconazole ,consensus set annotator team,158,170,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,saquinavir ,consensus set annotator team,183,193,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,erythromycin ,consensus set annotator team,195,207,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,desipramine ,consensus set annotator team,90,101,Active ingredient,propafenone ,consensus set annotator team,,283,294,Positive,Qualitative,"7 DRUG INTERACTIONS

7.1 CYP2D6 and CYP3A4 Inhibitors

Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.",consensus set annotator team,250,279
package-insert-section-194.txt,Active ingredient,cimetidine ,consensus set annotator team,891,901,Active ingredient,propafenone ,consensus set annotator team,,849,860,Positive,Quantitative,"Cimetidine

Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.",consensus set annotator team,939,989
package-insert-section-194.txt,Active ingredient,fluoxetine ,consensus set annotator team,1065,1075,Active ingredient,propafenone ,consensus set annotator team,,1049,1060,Positive,Quantitative,"Fluoxetine

Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.",consensus set annotator team,1102,1205
package-insert-section-194.txt,Active ingredient,quinidine ,consensus set annotator team,1421,1430,Active ingredient,propafenone ,consensus set annotator team,,1487,1498,Positive,Quantitative,"Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM.",consensus set annotator team,1599,1666
package-insert-section-194.txt,Active ingredient,quinidine ,consensus set annotator team,1724,1733,Active ingredient,propafenone ,consensus set annotator team,,1775,1786,Positive,Quantitative,A 100 mg dose of quinidine increased steady state concentrations of propafenone 3-fold.,consensus set annotator team,1734,1793
package-insert-section-194.txt,Active ingredient,rifampin ,consensus set annotator team,1888,1896,Active ingredient,propafenone ,consensus set annotator team,,1901,1912,Positive,Quantitative,"Rifampin

Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.",consensus set annotator team,1939,1996
package-insert-section-194.txt,Active ingredient,rifampin ,consensus set annotator team,1888,1896,Active ingredient,propafenone ,consensus set annotator team,,2159,2170,Positive,Quantitative,"Rifampin

Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.",consensus set annotator team,2141,2192
package-insert-section-194.txt,Active ingredient,rifampin ,consensus set annotator team,1888,1896,Active ingredient,propafenone ,consensus set annotator team,,2419,2430,Positive,Quantitative,"Rifampin

Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.",consensus set annotator team,2397,2446
package-insert-section-194.txt,Active ingredient,rifampin ,consensus set annotator team,1888,1896,Active ingredient,propafenone ,consensus set annotator team,,1978,1989,Positive,Quantitative,"Rifampin

Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.",consensus set annotator team,2058,2106
package-insert-section-194.txt,Active ingredient,rifampin ,consensus set annotator team,1888,1896,Active ingredient,propafenone ,consensus set annotator team,,1978,1989,Positive,Quantitative,"Rifampin

Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.",consensus set annotator team,2197,2254
package-insert-section-194.txt,Active ingredient,rifampin ,consensus set annotator team,1888,1896,Active ingredient,propafenone ,consensus set annotator team,,2419,2430,Positive,Quantitative,"Rifampin

Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.",consensus set annotator team,2470,2527
package-insert-section-194.txt,Active ingredient,propafenone ,consensus set annotator team,2562,2573,Active ingredient,digoxin ,consensus set annotator team,,2578,2585,Positive,Quantitative,"7.2 Digoxin

Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.",consensus set annotator team,2586,2663
package-insert-section-194.txt,Active ingredient,propafenone ,consensus set annotator team,2868,2879,Active ingredient,warfarin ,consensus set annotator team,,2884,2892,Positive,Quantitative,"7.3 Warfarin

The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.",consensus set annotator team,2893,2956
package-insert-section-194.txt,Active ingredient,propafenone ,consensus set annotator team,3474,3485,Active ingredient,propranolol ,consensus set annotator team,,3490,3501,Positive,Quantitative,"7.5 Beta-Antagonists

Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.",consensus set annotator team,3522,3589
package-insert-section-194.txt,Active ingredient,propafenone ,consensus set annotator team,3640,3651,Active ingredient,metoprolol ,consensus set annotator team,,3624,3634,Positive,Quantitative,"In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.",consensus set annotator team,3652,3726
package-insert-section-194.txt,Active ingredient,propranolol ,consensus set annotator team,3815,3826,Active ingredient,propafenone ,consensus set annotator team,,3752,3763,Negative,Qualitative,The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol.,consensus set annotator team,3728,3780
package-insert-section-194.txt,Active ingredient,metoprolol ,consensus set annotator team,3830,3840,Active ingredient,propafenone ,consensus set annotator team,,3867,3878,Negative,Qualitative,The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol.,consensus set annotator team,3728,3780
package-insert-section-194.txt,Active ingredient,propafenone ,consensus set annotator team,4086,4097,Active ingredient,lidocaine ,consensus set annotator team,,4101,4110,Negative,Qualitative,"7.6 Lidocaine

No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients.",consensus set annotator team,4036,4125
package-insert-section-194.txt,Active ingredient,lidocaine ,consensus set annotator team,4101,4110,Active ingredient,propafenone ,consensus set annotator team,,4086,4097,Negative,Qualitative,"7.6 Lidocaine

No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients.",consensus set annotator team,4036,4125
package-insert-section-197.txt,Active ingredient,zidovudine ,consensus set annotator team,5923,5933,Active ingredient,Phenytoin ,consensus set annotator team,,5843,5852,Positive,Qualitative,"Phenytoin:  Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented.",consensus set annotator team,5853,5895
package-insert-section-197.txt,Active ingredient,zidovudine ,consensus set annotator team,6138,6148,Active ingredient,phenytoin ,consensus set annotator team,,6093,6102,Negative,Qualitative,"However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed.",consensus set annotator team,6184,6215
package-insert-section-197.txt,Active ingredient,phenytoin ,consensus set annotator team,6286,6295,Active ingredient,zidovudine ,consensus set annotator team,,6299,6309,Positive,Quantitative,"Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.",consensus set annotator team,6322,6376
package-insert-section-197.txt,Active ingredient,ribavirin ,consensus set annotator team,6728,6737,Active ingredient,stavudine ,consensus set annotator team,,6763,6772,Negative,Qualitative,"However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].",consensus set annotator team,6514,6722
package-insert-section-197.txt,Active ingredient,ribavirin ,consensus set annotator team,6728,6737,Active ingredient,zidovudine ,consensus set annotator team,,6786,6796,Negative,Qualitative,"However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].",consensus set annotator team,6514,6722
package-insert-section-197.txt,Active ingredient,ribavirin ,consensus set annotator team,6728,6737,Active ingredient,lamivudine ,consensus set annotator team,,6742,6752,Negative,Qualitative,"However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].",consensus set annotator team,6514,6722
package-insert-section-198.txt,Active ingredient,methadone ,consensus set annotator team,66,75,Active ingredient,didanosine ,consensus set annotator team,,114,124,Positive,Qualitative,"Didanosine and Stavudine

Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine.",consensus set annotator team,76,109
package-insert-section-198.txt,Active ingredient,methadone ,consensus set annotator team,66,75,Active ingredient,stavudine ,consensus set annotator team,,129,138,Positive,Qualitative,"Didanosine and Stavudine

Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine.",consensus set annotator team,76,109
package-insert-section-199.txt,Active ingredient,methadone ,consensus set annotator team,52,61,Active ingredient,zidovudine ,consensus set annotator team,,125,135,Positive,Qualitative,"Zidovudine

Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.",consensus set annotator team,62,121
package-insert-section-200.txt,Active ingredient,rifampin ,consensus set annotator team,82,90,Active ingredient,methadone ,consensus set annotator team,,41,50,Positive,Qualitative,"Rifampin

In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.",consensus set annotator team,112,147
package-insert-section-201.txt,Active ingredient,phenytoin ,consensus set annotator team,86,95,Active ingredient,methadone ,consensus set annotator team,,55,64,Positive,Quantitative,"Phenytoin

In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d.initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently.",consensus set annotator team,214,249
package-insert-section-202.txt,Active ingredient,voriconazole ,consensus set annotator team,49,61,Active ingredient,methadone ,consensus set annotator team,,147,156,Positive,Quantitative,"Voriconazole

Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD).",consensus set annotator team,261,316
package-insert-section-202.txt,Active ingredient,voriconazole ,consensus set annotator team,49,61,Active ingredient,methadone ,consensus set annotator team,,281,290,Positive,Quantitative,"Voriconazole

Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD).",consensus set annotator team,261,316
package-insert-section-203.txt,Active ingredient,methadone ,consensus set annotator team,72,81,Active ingredient,desipramine ,consensus set annotator team,,29,40,Positive,Qualitative,"Desipramine

Blood levels of desipramine have increased with concurrent methadone administration.",consensus set annotator team,13,55
package-insert-section-207.txt,Active ingredient,omeprazole ,consensus set annotator team,597,607,Active ingredient,clopidogrel ,consensus set annotator team,,696,707,Positive,Quantitative,"Omeprazole

In a crossover clinical study, 72 healthy subjects were administered Plavix (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as Plavix) for 5 days.",consensus set annotator team,659,751
package-insert-section-207.txt,Active ingredient,omeprazole ,consensus set annotator team,769,779,Drug product,Plavix ,consensus set annotator team,,758,764,Positive,Quantitative,The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when Plavix and omeprazole were administered together.,consensus set annotator team,659,751
package-insert-section-207.txt,Active ingredient,clopidogrel ,consensus set annotator team,1465,1476,Active ingredient,warfarin ,consensus set annotator team,,1532,1540,Negative,Qualitative,"7.3 Warfarin (CYP2C9 Substrates)

Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis.",consensus set annotator team,1491,1526
package-insert-section-21.txt,Active ingredient,fluconazole ,consensus set annotator team,333,344,Active ingredient,norethindrone ,consensus set annotator team,,511,524,Positive,Qualitative,"In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing.",consensus set annotator team,352,396
package-insert-section-21.txt,Active ingredient,fluconazole ,consensus set annotator team,333,344,Active ingredient,ethinyl estradiol ,consensus set annotator team,,489,506,Positive,Qualitative,"In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing.",consensus set annotator team,352,396
package-insert-section-22.txt,Active ingredient,fluconazole ,consensus set annotator team,282,293,Active ingredient,ethinyl estradiol ,consensus set annotator team,,316,333,Negative,Qualitative,There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.,consensus set annotator team,176,244
package-insert-section-22.txt,Active ingredient,fluconazole ,consensus set annotator team,282,293,Active ingredient,levonorgestrel ,consensus set annotator team,,226,240,Negative,Qualitative,There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.,consensus set annotator team,176,244
package-insert-section-23.txt,Active ingredient,cimetidine ,consensus set annotator team,179,189,Active ingredient,fluconazole ,consensus set annotator team,,287,298,Positive,Quantitative,"After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax.",consensus set annotator team,275,385
package-insert-section-23.txt,Active ingredient,cimetidine ,consensus set annotator team,419,429,Active ingredient,fluconazole ,consensus set annotator team,,546,557,Negative,Qualitative,"However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.",consensus set annotator team,566,620
package-insert-section-24.txt,Active ingredient,rifampin ,consensus set annotator team,76,84,Active ingredient,Fluconazole ,consensus set annotator team,,435,446,Positive,Quantitative,Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole.,consensus set annotator team,447,508
package-insert-section-24.txt,Active ingredient,rifampin ,consensus set annotator team,76,84,Active ingredient,fluconazole ,consensus set annotator team,,47,58,Positive,Qualitative,Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole.,consensus set annotator team,161,200
package-insert-section-25.txt,Active ingredient,fluconazole ,consensus set annotator team,186,197,Active ingredient,phenytoin ,consensus set annotator team,,349,358,Positive,Quantitative,"Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.",consensus set annotator team,337,370
package-insert-section-26.txt,Active ingredient,fluconazole ,consensus set annotator team,81,92,Active ingredient,cyclosporine ,consensus set annotator team,,304,316,Positive,Qualitative,Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.,consensus set annotator team,280,332
package-insert-section-27.txt,Active ingredient,fluconazole ,consensus set annotator team,304,315,Active ingredient,zidovudine ,consensus set annotator team,,257,267,Positive,Qualitative,There was a significant increase in zidovudine AUC following the administration of fluconazole.,consensus set annotator team,233,271
package-insert-section-28.txt,Active ingredient,fluconazole ,consensus set annotator team,155,166,Active ingredient,theophylline ,consensus set annotator team,,354,366,Positive,Qualitative,The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.,consensus set annotator team,233,295
package-insert-section-28.txt,Active ingredient,fluconazole ,consensus set annotator team,155,166,Active ingredient,theophylline ,consensus set annotator team,,354,366,Positive,Qualitative,The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.,consensus set annotator team,233,295
package-insert-section-29.txt,Active ingredient,fluconazole ,consensus set annotator team,142,153,Active ingredient,Tolbutamide ,consensus set annotator team,,237,248,Positive,Quantitative,"In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole.",consensus set annotator team,237,267
package-insert-section-29.txt,Active ingredient,fluconazole ,consensus set annotator team,142,153,Active ingredient,tolbutamide ,consensus set annotator team,,189,200,Positive,Quantitative,"In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole.",consensus set annotator team,177,211
package-insert-section-30.txt,Active ingredient,fluconazole ,consensus set annotator team,112,123,Active ingredient,glipizide ,consensus set annotator team,,20,29,Positive,Qualitative,The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers.,consensus set annotator team,0,79
package-insert-section-31.txt,Active ingredient,fluconazole ,consensus set annotator team,110,121,Active ingredient,glyburide ,consensus set annotator team,,20,29,Positive,Qualitative,The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers.,consensus set annotator team,0,77
package-insert-section-32.txt,Active ingredient,Fluconazole ,consensus set annotator team,441,452,Active ingredient,midazolam ,consensus set annotator team,,481,490,Positive,Quantitative,Fluconazole reduced the clearance of IV midazolam by 51%.,consensus set annotator team,453,497
package-insert-section-32.txt,Active ingredient,fluconazole ,consensus set annotator team,527,538,Active ingredient,midazolam ,consensus set annotator team,,553,562,Positive,Quantitative,"On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively.",consensus set annotator team,539,592
package-insert-section-32.txt,Active ingredient,fluconazole ,consensus set annotator team,636,647,Active ingredient,midazolam ,consensus set annotator team,,662,671,Positive,Quantitative,"On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively.",consensus set annotator team,648,700
package-insert-section-33.txt,Active ingredient,fluconazole ,consensus set annotator team,350,361,Active ingredient,azithromycin ,consensus set annotator team,,366,378,Negative,Qualitative,There was no significant pharmacokinetic interaction between fluconazole and azithromycin.,consensus set annotator team,299,341
package-insert-section-33.txt,Active ingredient,azithromycin ,consensus set annotator team,366,378,Active ingredient,fluconazole ,consensus set annotator team,,350,361,Negative,Qualitative,There was no significant pharmacokinetic interaction between fluconazole and azithromycin.,consensus set annotator team,299,341
package-insert-section-35.txt,Active ingredient,magnesium ,consensus set annotator team,20,29,Active ingredient,nitrofurantoin ,consensus set annotator team,,80,94,Positive,Qualitative,"Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.",consensus set annotator team,96,141
package-insert-section-36.txt,Active ingredient,probenecid ,consensus set annotator team,26,36,Active ingredient,nitrofurantoin ,consensus set annotator team,,138,152,Positive,Qualitative,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",consensus set annotator team,126,165
package-insert-section-36.txt,Active ingredient,sulfinpyrazone ,consensus set annotator team,41,55,Active ingredient,nitrofurantoin ,consensus set annotator team,,138,152,Positive,Qualitative,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",consensus set annotator team,126,165
package-insert-section-38.txt,Active ingredient,fluvoxamine ,consensus set annotator team,296,307,Active ingredient,thioridazine ,consensus set annotator team,,172,184,Positive,Quantitative,"Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.",consensus set annotator team,154,265
package-insert-section-38.txt,Active ingredient,fluvoxamine ,consensus set annotator team,296,307,Metabolite,mesoridazine ,consensus set annotator team,thioridazine ,217,229,Positive,Quantitative,"Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.",consensus set annotator team,154,265
package-insert-section-38.txt,Active ingredient,fluvoxamine ,consensus set annotator team,296,307,Metabolite,sulforidazine ,consensus set annotator team,thioridazine ,234,247,Positive,Quantitative,"Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.",consensus set annotator team,154,265
package-insert-section-40.txt,Active ingredient,fluconazole ,consensus set annotator team,586,597,Active ingredient,glipizide ,consensus set annotator team,,566,575,Positive,Quantitative,The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).,consensus set annotator team,539,622
package-insert-section-42.txt,Active ingredient,allopurinol ,consensus set annotator team,105,116,Active ingredient,mercaptopurine ,consensus set annotator team,,241,255,Positive,Quantitative,"In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",consensus set annotator team,159,237
package-insert-section-42.txt,Active ingredient,allopurinol ,consensus set annotator team,105,116,Active ingredient,azathioprine ,consensus set annotator team,,259,271,Positive,Quantitative,"In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",consensus set annotator team,159,237
package-insert-section-44.txt,Active ingredient,paroxetine ,consensus set annotator team,69,79,Active ingredient,pimozide ,consensus set annotator team,,213,221,Positive,Quantitative,"In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.",consensus set annotator team,200,249
package-insert-section-45.txt,Active ingredient,phenobarbital ,consensus set annotator team,147,160,Active ingredient,paroxetine ,consensus set annotator team,,115,125,Positive,Quantitative,"When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.",consensus set annotator team,218,271
package-insert-section-46.txt,Active ingredient,phenytoin ,consensus set annotator team,83,92,Active ingredient,paroxetine ,consensus set annotator team,,51,61,Positive,Quantitative,"When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.",consensus set annotator team,150,203
package-insert-section-46.txt,Active ingredient,paroxetine ,consensus set annotator team,365,375,Active ingredient,phenytoin ,consensus set annotator team,,335,344,Positive,Quantitative,"In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.",consensus set annotator team,431,472
package-insert-section-47.txt,Active ingredient,paroxetine ,consensus set annotator team,445,455,Active ingredient,desipramine ,consensus set annotator team,,528,539,Positive,Quantitative,"In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T by an average of approximately 2-, 5-, and 3-fold, respectively.",consensus set annotator team,506,616
package-insert-section-47.txt,Active ingredient,paroxetine ,consensus set annotator team,752,762,Active ingredient,risperidone ,consensus set annotator team,,1024,1035,Positive,Quantitative,"In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.",consensus set annotator team,966,1085
package-insert-section-47.txt,Active ingredient,paroxetine ,consensus set annotator team,752,762,Active ingredient,risperidone ,consensus set annotator team,,863,874,Positive,Quantitative,"In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.",consensus set annotator team,823,895
package-insert-section-47.txt,Active ingredient,paroxetine ,consensus set annotator team,752,762,Metabolite,9-hydroxyrisperidone ,consensus set annotator team,risperidone ,907,927,Positive,Quantitative,"In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.",consensus set annotator team,897,960
package-insert-section-47.txt,Active ingredient,paroxetine ,consensus set annotator team,1273,1283,Active ingredient,atomoxetine ,consensus set annotator team,,1464,1475,Positive,Quantitative,"In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.",consensus set annotator team,1464,1518
package-insert-section-47.txt,Active ingredient,paroxetine ,consensus set annotator team,1273,1283,Active ingredient,atomoxetine ,consensus set annotator team,,1403,1414,Positive,Quantitative,"In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.",consensus set annotator team,1377,1456
package-insert-section-48.txt,Active ingredient,paroxetine ,consensus set annotator team,93,103,Active ingredient,terfenadine ,consensus set annotator team,,108,119,Negative,Qualitative,"An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for  CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.",consensus set annotator team,155,210
package-insert-section-49.txt,Active ingredient,paroxetine ,consensus set annotator team,133,143,Active ingredient,lithium ,consensus set annotator team,,148,155,Negative,Qualitative,A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.,consensus set annotator team,94,124
package-insert-section-49.txt,Active ingredient,lithium ,consensus set annotator team,148,155,Active ingredient,paroxetine ,consensus set annotator team,,133,143,Negative,Qualitative,A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.,consensus set annotator team,94,124
package-insert-section-5.txt,Active ingredient,ethanol ,consensus set annotator team,51,58,Metabolite,O-desmethylvenlafaxine ,consensus set annotator team,venlafaxine ,126,148,Negative,Qualitative,"7 DRUG INTERACTIONS

7.1 Alcohol

A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.",consensus set annotator team,74,107
package-insert-section-5.txt,Active ingredient,ethanol ,consensus set annotator team,51,58,Active ingredient,venlafaxine ,consensus set annotator team,,111,122,Negative,Qualitative,"7 DRUG INTERACTIONS

7.1 Alcohol

A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.",consensus set annotator team,74,107
package-insert-section-5.txt,Active ingredient,cimetidine ,consensus set annotator team,487,497,Active ingredient,venlafaxine ,consensus set annotator team,,502,513,Positive,Qualitative,"7.2 Cimetidine

Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.",consensus set annotator team,553,600
package-insert-section-5.txt,Active ingredient,cimetidine ,consensus set annotator team,487,497,Active ingredient,venlafaxine ,consensus set annotator team,,662,673,Positive,Quantitative,"7.2 Cimetidine

Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.",consensus set annotator team,704,794
package-insert-section-5.txt,Active ingredient,cimetidine ,consensus set annotator team,826,836,Metabolite,ODV ,consensus set annotator team,venlafaxine ,887,890,Negative,Qualitative,"However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.",consensus set annotator team,841,883
package-insert-section-5.txt,Active ingredient,diazepam ,consensus set annotator team,1556,1564,Active ingredient,venlafaxine ,consensus set annotator team,,1493,1504,Negative,Qualitative,"7.3 Diazepam

Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.",consensus set annotator team,1565,1610
package-insert-section-5.txt,Active ingredient,diazepam ,consensus set annotator team,1556,1564,Active ingredient,venlafaxine ,consensus set annotator team,,1621,1632,Negative,Qualitative,"7.3 Diazepam

Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.",consensus set annotator team,1565,1639
package-insert-section-5.txt,Active ingredient,diazepam ,consensus set annotator team,1556,1564,Metabolite,ODV ,consensus set annotator team,venlafaxine ,1636,1639,Negative,Qualitative,"7.3 Diazepam

Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.",consensus set annotator team,1565,1639
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,1669,1680,Active ingredient,diazepam ,consensus set annotator team,,1737,1745,Negative,Qualitative,"Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.",consensus set annotator team,1686,1709
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,1669,1680,Metabolite,desmethyldiazepam ,consensus set annotator team,diazepam ,1772,1789,Negative,Qualitative,"Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.",consensus set annotator team,1686,1709
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,1881,1892,Active ingredient,haloperidol ,consensus set annotator team,,2131,2142,Positive,Quantitative,"7.4 Haloperidol

Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.",consensus set annotator team,2143,2160
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,1881,1892,Active ingredient,haloperidol ,consensus set annotator team,,2041,2052,Positive,Quantitative,"7.4 Haloperidol

Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.",consensus set annotator team,2067,2112
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,2187,2198,Active ingredient,haloperidol ,consensus set annotator team,,2131,2142,Positive,Quantitative,"In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.",consensus set annotator team,2143,2160
package-insert-section-5.txt,Active ingredient,lithium ,consensus set annotator team,2456,2463,Metabolite,ODV ,consensus set annotator team,venlafaxine ,2510,2513,Negative,Qualitative,"7.5 Lithium

The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.",consensus set annotator team,2551,2584
package-insert-section-5.txt,Active ingredient,lithium ,consensus set annotator team,2456,2463,Active ingredient,venlafaxine ,consensus set annotator team,,2365,2376,Negative,Qualitative,"7.5 Lithium

The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.",consensus set annotator team,2345,2421
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,2535,2546,Active ingredient,lithium ,consensus set annotator team,,2588,2595,Negative,Qualitative,"Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).",consensus set annotator team,2551,2584
package-insert-section-5.txt,Active ingredient,ketoconazole ,consensus set annotator team,3872,3884,Active ingredient,venlafaxine ,consensus set annotator team,,3921,3932,Positive,Qualitative,Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.,consensus set annotator team,4026,4066
package-insert-section-5.txt,Active ingredient,ketoconazole ,consensus set annotator team,3872,3884,Metabolite,O-desmethylvenlafaxine ,consensus set annotator team,venlafaxine ,4091,4113,Positive,Qualitative,Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.,consensus set annotator team,4026,4066
package-insert-section-5.txt,Active ingredient,ketoconazole ,consensus set annotator team,4165,4177,Metabolite,ODV ,consensus set annotator team,Venlafaxine ,4454,4457,Positive,Quantitative,Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.,consensus set annotator team,4347,4405
package-insert-section-5.txt,Active ingredient,ketoconazole ,consensus set annotator team,4165,4177,Metabolite,ODV ,consensus set annotator team,Venlafaxine ,4268,4271,Positive,Quantitative,Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.,consensus set annotator team,4191,4250
package-insert-section-5.txt,Active ingredient,ketoconazole ,consensus set annotator team,4165,4177,Active ingredient,Venlafaxine ,consensus set annotator team,,4335,4346,Positive,Quantitative,Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.,consensus set annotator team,4347,4405
package-insert-section-5.txt,Active ingredient,ketoconazole ,consensus set annotator team,4165,4177,Active ingredient,Venlafaxine ,consensus set annotator team,,4179,4190,Positive,Quantitative,Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.,consensus set annotator team,4191,4250
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,5256,5267,Metabolite,2-OH-imipramine ,consensus set annotator team,imipramine ,5322,5337,Negative,Qualitative,Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.,consensus set annotator team,5268,5303
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,5256,5267,Active ingredient,imipramine ,consensus set annotator team,,5307,5317,Negative,Qualitative,Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.,consensus set annotator team,5268,5303
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,5422,5433,Active ingredient,desipramine ,consensus set annotator team,,5348,5359,Positive,Quantitative,The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).,consensus set annotator team,5360,5402
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,5499,5510,Metabolite,2-OH-desipramine ,consensus set annotator team,imipramine ,5439,5455,Positive,Quantitative,The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).,consensus set annotator team,5456,5540
package-insert-section-5.txt,Active ingredient,Imipramine ,consensus set annotator team,5572,5582,Metabolite,ODV ,consensus set annotator team,venlafaxine ,5638,5641,Negative,Qualitative,Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.,consensus set annotator team,5583,5618
package-insert-section-5.txt,Active ingredient,Imipramine ,consensus set annotator team,5572,5582,Active ingredient,venlafaxine ,consensus set annotator team,,5622,5633,Negative,Qualitative,Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.,consensus set annotator team,5583,5618
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,5761,5772,Metabolite,?-hydroxymetoprolol ,consensus set annotator team,metoprolol ,6097,6116,Negative,Qualitative,"Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.",consensus set annotator team,6028,6116
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,5761,5772,Active ingredient,metoprolol ,consensus set annotator team,,5990,6000,Positive,Quantitative,"Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.",consensus set annotator team,5950,6027
package-insert-section-5.txt,Active ingredient,Metoprolol ,consensus set annotator team,6118,6128,Active ingredient,venlafaxine ,consensus set annotator team,,6174,6185,Negative,Qualitative,"Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.",consensus set annotator team,6129,6170
package-insert-section-5.txt,Active ingredient,Metoprolol ,consensus set annotator team,6118,6128,Metabolite,O-desmethylvenlafaxine ,consensus set annotator team,venlafaxine ,6212,6234,Negative,Qualitative,"Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.",consensus set annotator team,6129,6170
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,6788,6799,Active ingredient,risperidone ,consensus set annotator team,,7056,7067,Positive,Quantitative,"Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.",consensus set annotator team,7040,7071
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,7082,7093,Active ingredient,risperidone ,consensus set annotator team,,7195,7206,Negative,Qualitative,"However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).",consensus set annotator team,7111,7193
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,7370,7381,Active ingredient,terfenadine ,consensus set annotator team,,7479,7490,Negative,Qualitative,"This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.",consensus set annotator team,7382,7412
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,7370,7381,Active ingredient,diazepam ,consensus set annotator team,,7465,7473,Negative,Qualitative,"This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.",consensus set annotator team,7382,7412
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,7370,7381,Active ingredient,alprazolam ,consensus set annotator team,,7453,7463,Negative,Qualitative,"This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.",consensus set annotator team,7382,7412
package-insert-section-5.txt,Active ingredient,Indinavir ,consensus set annotator team,7728,7737,Metabolite,ODV ,consensus set annotator team,venlafaxine ,7793,7796,Negative,Qualitative,Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.,consensus set annotator team,7738,7773
package-insert-section-5.txt,Active ingredient,Indinavir ,consensus set annotator team,7728,7737,Active ingredient,venlafaxine ,consensus set annotator team,,7777,7788,Negative,Qualitative,Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.,consensus set annotator team,7738,7773
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,7861,7872,Active ingredient,caffeine ,consensus set annotator team,,8033,8041,Negative,Qualitative,"CYP1A2

Venlafaxine did not inhibit CYP1A2 in vitro.",consensus set annotator team,7999,8029
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,8073,8084,Active ingredient,tolbutamide ,consensus set annotator team,,8231,8242,Negative,Quantitative,"CYP2C9
 
Venlafaxine did not inhibit CYP2C9 in vitro.",consensus set annotator team,8169,8203
package-insert-section-5.txt,Active ingredient,Venlafaxine ,consensus set annotator team,8312,8323,Active ingredient,diazepam ,consensus set annotator team,,8358,8366,Negative,Qualitative,"CYP2C19

Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).",consensus set annotator team,8324,8354
package-insert-section-5.txt,Active ingredient,venlafaxine ,consensus set annotator team,11366,11377,Active ingredient,clozapine ,consensus set annotator team,,11247,11256,Positive,Qualitative,"There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.",consensus set annotator team,11227,11263
package-insert-section-50.txt,Active ingredient,paroxetine ,consensus set annotator team,39,49,Active ingredient,procyclidine ,consensus set annotator team,,126,138,Positive,Quantitative,"Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state.",consensus set annotator team,69,182
package-insert-section-51.txt,Active ingredient,fosamprenavir/ritonavir ,consensus set annotator team,21,44,Active ingredient,paroxetine ,consensus set annotator team,,50,60,Positive,Qualitative,Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.,consensus set annotator team,61,98
package-insert-section-53.txt,Active ingredient,ketoconazole ,consensus set annotator team,93,105,Active ingredient,quinidine ,consensus set annotator team,,66,75,Positive,Qualitative,"Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.",consensus set annotator team,66,123
package-insert-section-54.txt,Active ingredient,Diltiazem ,consensus set annotator team,0,9,Active ingredient,quinidine ,consensus set annotator team,,74,83,Positive,Qualitative,"Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.",consensus set annotator team,24,83
package-insert-section-54.txt,Active ingredient,quinidine ,consensus set annotator team,89,98,Active ingredient,diltiazem ,consensus set annotator team,,130,139,Negative,Qualitative,"Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.",consensus set annotator team,99,126
package-insert-section-56.txt,Active ingredient,Zonisamide ,consensus set annotator team,0,10,Active ingredient,phenytoin ,consensus set annotator team,,82,91,Negative,Qualitative,"Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.",consensus set annotator team,15,78
package-insert-section-56.txt,Active ingredient,Zonisamide ,consensus set annotator team,0,10,Active ingredient,carbamazepine ,consensus set annotator team,,93,106,Negative,Qualitative,"Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.",consensus set annotator team,15,78
package-insert-section-56.txt,Active ingredient,Zonisamide ,consensus set annotator team,0,10,Active ingredient,valproate ,consensus set annotator team,,111,120,Negative,Qualitative,"Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.",consensus set annotator team,15,78
package-insert-section-57.txt,Active ingredient,cimetidine ,consensus set annotator team,71,81,Active ingredient,Zonisamide ,consensus set annotator team,,0,10,Negative,Qualitative,Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).,consensus set annotator team,23,67
package-insert-section-59.txt,Active ingredient,carbamazepine ,consensus set annotator team,20,33,Active ingredient,nefazodone ,consensus set annotator team,,39,49,Positive,Qualitative,Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect.,consensus set annotator team,50,95
package-insert-section-63.txt,Active ingredient,cimetidine ,consensus set annotator team,100,110,Active ingredient,nisoldipine ,consensus set annotator team,,40,51,Positive,Quantitative,A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.,consensus set annotator team,0,64
package-insert-section-63.txt,Active ingredient,Ranitidine ,consensus set annotator team,131,141,Active ingredient,nisoldipine ,consensus set annotator team,,197,208,Negative,Quantitative,Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).,consensus set annotator team,161,238
package-insert-section-63.txt,Active ingredient,phenytoin ,consensus set annotator team,465,474,Active ingredient,nisoldipine ,consensus set annotator team,,564,575,Positive,Qualitative,Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.,consensus set annotator team,552,620
package-insert-section-63.txt,Active ingredient,phenytoin ,consensus set annotator team,465,474,Active ingredient,Nisoldipine ,consensus set annotator team,,510,521,Positive,Qualitative,Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.,consensus set annotator team,552,620
package-insert-section-63.txt,Active ingredient,nisoldipine ,consensus set annotator team,787,798,Active ingredient,atenolol ,consensus set annotator team,,818,826,Negative,Qualitative,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.",consensus set annotator team,750,874
package-insert-section-63.txt,Active ingredient,nisoldipine ,consensus set annotator team,787,798,Active ingredient,propranolol ,consensus set annotator team,,828,839,Negative,Qualitative,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.",consensus set annotator team,750,874
package-insert-section-63.txt,Active ingredient,atenolol ,consensus set annotator team,818,826,Active ingredient,nisoldipine ,consensus set annotator team,,787,798,Negative,Qualitative,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.",consensus set annotator team,750,874
package-insert-section-63.txt,Active ingredient,propranolol ,consensus set annotator team,828,839,Active ingredient,nisoldipine ,consensus set annotator team,,787,798,Negative,Qualitative,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.",consensus set annotator team,750,874
package-insert-section-63.txt,Active ingredient,Quinidine ,consensus set annotator team,1123,1132,Active ingredient,nisoldipine ,consensus set annotator team,,1186,1197,Positive,Quantitative,"Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.",consensus set annotator team,1147,1236
package-insert-section-63.txt,Active ingredient,nisoldipine ,consensus set annotator team,1256,1267,Active ingredient,quinidine ,consensus set annotator team,,1285,1294,Positive,Quantitative,Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.,consensus set annotator team,1268,1322
package-insert-section-65.txt,Active ingredient,nefazodone ,consensus set annotator team,69,79,Active ingredient,triazolam ,consensus set annotator team,,110,119,Positive,Quantitative,"When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold.",consensus set annotator team,120,197
package-insert-section-65.txt,Active ingredient,triazolam ,consensus set annotator team,251,260,Active ingredient,Nefazodone ,consensus set annotator team,,199,209,Negative,Qualitative,Nefazodone plasma concentrations were unaffected by triazolam.,consensus set annotator team,210,247
package-insert-section-66.txt,Active ingredient,nefazodone ,consensus set annotator team,31,41,Active ingredient,alprazolam ,consensus set annotator team,,5,15,Positive,Quantitative,"When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold.",consensus set annotator team,89,183
package-insert-section-66.txt,Active ingredient,alprazolam ,consensus set annotator team,237,247,Active ingredient,Nefazodone ,consensus set annotator team,,185,195,Negative,Qualitative,Nefazodone plasma concentrations were unaffected by alprazolam.,consensus set annotator team,196,233
package-insert-section-68.txt,Active ingredient,rifampin ,consensus set annotator team,18,26,Active ingredient,bisoprolol ,consensus set annotator team,,64,74,Positive,Qualitative,Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.,consensus set annotator team,27,120
package-insert-section-68.txt,Active ingredient,cimetidine ,consensus set annotator team,326,336,Active ingredient,bisoprolol ,consensus set annotator team,,64,74,Negative,Qualitative,"Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.",consensus set annotator team,218,253
package-insert-section-7.txt,Active ingredient,Amitriptyline ,consensus set annotator team,534,547,Metabolite,9-hydroxyrisperidone ,consensus set annotator team,risperidone ,618,638,Negative,Qualitative,"7.4 Amitriptyline

Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.",consensus set annotator team,548,583
package-insert-section-7.txt,Active ingredient,Amitriptyline ,consensus set annotator team,534,547,Active ingredient,risperidone ,consensus set annotator team,,587,598,Negative,Qualitative,"7.4 Amitriptyline

Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.",consensus set annotator team,548,583
package-insert-section-7.txt,Active ingredient,Cimetidine ,consensus set annotator team,681,691,Active ingredient,risperidone ,consensus set annotator team,,740,751,Positive,Quantitative,"7.5 Cimetidine and Ranitidine

Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.",consensus set annotator team,707,765
package-insert-section-7.txt,Active ingredient,ranitidine ,consensus set annotator team,696,706,Active ingredient,risperidone ,consensus set annotator team,,740,751,Positive,Quantitative,"7.5 Cimetidine and Ranitidine

Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.",consensus set annotator team,707,765
package-insert-section-7.txt,Active ingredient,ranitidine ,consensus set annotator team,883,893,Active ingredient,risperidone ,consensus set annotator team,,915,926,Positive,Quantitative,"However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.",consensus set annotator team,894,967
package-insert-section-7.txt,Active ingredient,clozapine ,consensus set annotator team,1011,1020,Active ingredient,risperidone ,consensus set annotator team,,1026,1037,Positive,Qualitative,"7.6 Clozapine

Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.",consensus set annotator team,1038,1064
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,1118,1129,Active ingredient,lithium ,consensus set annotator team,,1223,1230,Negative,Qualitative,"7.7 Lithium

Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).",consensus set annotator team,1149,1218
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,1278,1289,Active ingredient,valproate ,consensus set annotator team,,1391,1400,Negative,Qualitative,"7.8 Valproate

Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).",consensus set annotator team,1308,1386
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,1582,1593,Active ingredient,valproate ,consensus set annotator team,,1503,1512,Positive,Quantitative,"However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.",consensus set annotator team,1475,1544
package-insert-section-7.txt,Active ingredient,Risperidone ,consensus set annotator team,1609,1620,Active ingredient,digoxin ,consensus set annotator team,,1712,1719,Negative,Qualitative,"7.9 Digoxin

Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.",consensus set annotator team,1643,1708
package-insert-section-7.txt,Active ingredient,Fluoxetine ,consensus set annotator team,2619,2629,Active ingredient,risperidone ,consensus set annotator team,,2739,2750,Positive,Quantitative,"Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.",consensus set annotator team,2702,2782
package-insert-section-7.txt,Active ingredient,paroxetine ,consensus set annotator team,2653,2663,Active ingredient,risperidone ,consensus set annotator team,,2739,2750,Positive,Quantitative,"Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.",consensus set annotator team,2702,2782
package-insert-section-7.txt,Active ingredient,Fluoxetine ,consensus set annotator team,2798,2808,Metabolite,9-hydroxyrisperidone ,consensus set annotator team,risperidone ,2852,2872,Negative,Qualitative,Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.,consensus set annotator team,2809,2848
package-insert-section-7.txt,Active ingredient,Paroxetine ,consensus set annotator team,2874,2884,Metabolite,9-hydroxyrisperidone ,consensus set annotator team,risperidone ,2914,2934,Positive,Quantitative,Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.,consensus set annotator team,2885,2947
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,3315,3326,Active ingredient,erythromycin ,consensus set annotator team,,3331,3343,Negative,Qualitative,Erythromycin:There were no significant interactions between risperidone and erythromycin.,consensus set annotator team,3268,3306
package-insert-section-7.txt,Active ingredient,Carbamazepine ,consensus set annotator team,3392,3405,Metabolite,9-hydroxyrisperidone ,consensus set annotator team,risperidone ,3492,3512,Positive,Quantitative,"7.11 Carbamazepine and Other Enzyme Inducers

Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.",consensus set annotator team,3424,3525
package-insert-section-7.txt,Active ingredient,Carbamazepine ,consensus set annotator team,3392,3405,Active ingredient,risperidone ,consensus set annotator team,,3476,3487,Positive,Quantitative,"7.11 Carbamazepine and Other Enzyme Inducers

Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.",consensus set annotator team,3424,3525
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,3476,3487,Active ingredient,carbamazepine ,consensus set annotator team,,3552,3565,Negative,Quantitative,"7.11 Carbamazepine and Other Enzyme Inducers

Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.",consensus set annotator team,3534,3595
package-insert-section-7.txt,Active ingredient,phenytoin ,consensus set annotator team,3827,3836,Active ingredient,risperidone ,consensus set annotator team,,3872,3883,Positive,Qualitative,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.",consensus set annotator team,3884,3949
package-insert-section-7.txt,Active ingredient,rifampin ,consensus set annotator team,3838,3846,Active ingredient,risperidone ,consensus set annotator team,,3872,3883,Positive,Qualitative,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.",consensus set annotator team,3884,3949
package-insert-section-7.txt,Active ingredient,phenobarbital ,consensus set annotator team,3852,3865,Active ingredient,risperidone ,consensus set annotator team,,3872,3883,Positive,Qualitative,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.",consensus set annotator team,3884,3949
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,4342,4353,Active ingredient,galantamine ,consensus set annotator team,,4421,4432,Negative,Qualitative,"In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.",consensus set annotator team,4354,4403
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,4342,4353,Active ingredient,galantamine ,consensus set annotator team,,4421,4432,Negative,Qualitative,"In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.",consensus set annotator team,4354,4403
package-insert-section-7.txt,Active ingredient,risperidone ,consensus set annotator team,4342,4353,Active ingredient,donepezil ,consensus set annotator team,,4407,4416,Negative,Qualitative,"In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.",consensus set annotator team,4354,4403
package-insert-section-70.txt,Active ingredient,aluminum ,consensus set annotator team,64,72,Active ingredient,sotalol ,consensus set annotator team,,18,25,Positive,Quantitative,"Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest.",consensus set annotator team,148,188
package-insert-section-70.txt,Active ingredient,magnesium ,consensus set annotator team,83,92,Active ingredient,sotalol ,consensus set annotator team,,18,25,Positive,Quantitative,"Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest.",consensus set annotator team,148,188
package-insert-section-72.txt,Active ingredient,voriconazole ,consensus set annotator team,1123,1135,Active ingredient,oxycodone ,consensus set annotator team,,1210,1219,Positive,Qualitative,"7.4 Agents Affecting Cytochrome P450 Enzymes

CYP3A4 Inhibitors
A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.",consensus set annotator team,1171,1206
package-insert-section-72.txt,Active ingredient,rifampin ,consensus set annotator team,1800,1808,Active ingredient,oxycodone ,consensus set annotator team,,1877,1886,Positive,Qualitative,"[see Clinical Pharmacology (12.3)]

CYP3A4 Inducers
A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.",consensus set annotator team,1860,1901
package-insert-section-73.txt,Active ingredient,voriconazole ,consensus set annotator team,6794,6806,Active ingredient,oxycodone ,consensus set annotator team,,6838,6847,Positive,Quantitative,"A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.",consensus set annotator team,6828,6880
package-insert-section-73.txt,Active ingredient,rifampin ,consensus set annotator team,6968,6976,Active ingredient,oxycodone ,consensus set annotator team,,7024,7033,Positive,Quantitative,"CYP3A4 Inducers
A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.",consensus set annotator team,7014,7068
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,189,199,Active ingredient,iron ,consensus set annotator team,,353,357,Positive,Qualitative,"7 DRUG INTERACTIONS

Drugs for which gastric pH can affect bioavailability

Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).",consensus set annotator team,204,229
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,189,199,Active ingredient,ampicillin ,consensus set annotator team,,330,340,Positive,Qualitative,"7 DRUG INTERACTIONS

Drugs for which gastric pH can affect bioavailability

Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).",consensus set annotator team,204,229
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,189,199,Active ingredient,ketoconazole ,consensus set annotator team,,316,328,Positive,Qualitative,"7 DRUG INTERACTIONS

Drugs for which gastric pH can affect bioavailability

Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).",consensus set annotator team,204,229
package-insert-section-74.txt,Active ingredient,Omeprazole ,consensus set annotator team,536,546,Active ingredient,diazepam ,consensus set annotator team,,578,586,Positive,Qualitative,"Drugs metabolized by cytochrome P450 (CYP)

Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.",consensus set annotator team,551,574
package-insert-section-74.txt,Active ingredient,Omeprazole ,consensus set annotator team,536,546,Active ingredient,warfarin ,consensus set annotator team,,588,596,Positive,Qualitative,"Drugs metabolized by cytochrome P450 (CYP)

Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.",consensus set annotator team,551,574
package-insert-section-74.txt,Active ingredient,Omeprazole ,consensus set annotator team,536,546,Active ingredient,phenytoin ,consensus set annotator team,,601,610,Positive,Qualitative,"Drugs metabolized by cytochrome P450 (CYP)

Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.",consensus set annotator team,551,574
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,1408,1418,Active ingredient,theophylline ,consensus set annotator team,,1083,1095,Negative,Qualitative,Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.,consensus set annotator team,1063,1077
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,1408,1418,Active ingredient,propranolol ,consensus set annotator team,,1099,1110,Negative,Qualitative,Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.,consensus set annotator team,1063,1077
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,1408,1418,Active ingredient,cyclosporine ,consensus set annotator team,,1237,1249,Positive,Qualitative,Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.,consensus set annotator team,1147,1229
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,1408,1418,Active ingredient,disulfiram ,consensus set annotator team,,1251,1261,Positive,Qualitative,Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.,consensus set annotator team,1147,1229
package-insert-section-74.txt,Active ingredient,voriconazole ,consensus set annotator team,1495,1507,Active ingredient,omeprazole ,consensus set annotator team,,1480,1490,Positive,Quantitative,Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.,consensus set annotator team,1562,1610
package-insert-section-74.txt,Active ingredient,voriconazole ,consensus set annotator team,1809,1821,Active ingredient,omeprazole ,consensus set annotator team,,1881,1891,Positive,Quantitative,"When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.",consensus set annotator team,1958,2087
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,2122,2132,Active ingredient,atazanavir ,consensus set annotator team,,2364,2374,Positive,Qualitative,"When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.",consensus set annotator team,2341,2396
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,2896,2906,Active ingredient,nelfinavir ,consensus set annotator team,,2817,2827,Positive,Qualitative,"For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole.",consensus set annotator team,2829,2870
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,2896,2906,Active ingredient,atazanavir ,consensus set annotator team,,2802,2812,Positive,Qualitative,"For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole.",consensus set annotator team,2829,2870
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,2966,2976,Metabolite,M8 ,consensus set annotator team,nelfinavir ,3100,3102,Positive,Quantitative,"Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8.",consensus set annotator team,2990,3067
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,2966,2976,Active ingredient,nelfinavir ,consensus set annotator team,,2936,2946,Positive,Quantitative,"Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8.",consensus set annotator team,2990,3067
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,3160,3170,Active ingredient,atazanavir ,consensus set annotator team,,3132,3142,Positive,Quantitative,"Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.",consensus set annotator team,3208,3262
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,3626,3636,Active ingredient,saquinavir ,consensus set annotator team,,3421,3431,Positive,Quantitative,"For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.",consensus set annotator team,3482,3540
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,3626,3636,Active ingredient,saquinavir ,consensus set annotator team,,3570,3580,Positive,Quantitative,"For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.",consensus set annotator team,3433,3540
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,3626,3636,Active ingredient,ritonavir ,consensus set annotator team,,3581,3590,Positive,Quantitative,"For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.",consensus set annotator team,3433,3540
package-insert-section-74.txt,Active ingredient,omeprazole ,consensus set annotator team,3943,3953,Active ingredient,tacrolimus ,consensus set annotator team,,3958,3968,Positive,Qualitative,"Tacrolimus

Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus. ",consensus set annotator team,3969,3998
package-insert-section-75.txt,Active ingredient,clarithromycin ,consensus set annotator team,7604,7618,Active ingredient,omeprazole ,consensus set annotator team,,7714,7724,Positive,Quantitative,"Combination Therapy with Antimicrobials

Omeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects.",consensus set annotator team,7730,7793
package-insert-section-75.txt,Active ingredient,omeprazole ,consensus set annotator team,8230,8240,Metabolite,14-hydroxy-clarithromycin ,consensus set annotator team,clarithromycin ,8152,8177,Positive,Qualitative,"For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.",consensus set annotator team,8112,8192
package-insert-section-75.txt,Active ingredient,omeprazole ,consensus set annotator team,8402,8412,Metabolite,14-hydroxy-clarithromycin ,consensus set annotator team,clarithromycin ,8492,8517,Positive,Quantitative,"For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.",consensus set annotator team,8523,8616
package-insert-section-75.txt,Active ingredient,omeprazole ,consensus set annotator team,8230,8240,Active ingredient,clarithromycin ,consensus set annotator team,,8133,8147,Positive,Qualitative,"For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.",consensus set annotator team,8112,8192
package-insert-section-75.txt,Active ingredient,omeprazole ,consensus set annotator team,8402,8412,Active ingredient,clarithromycin ,consensus set annotator team,,8246,8260,Positive,Quantitative,"For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.",consensus set annotator team,8266,8359
package-insert-section-76.txt,Active ingredient,cimetidine ,consensus set annotator team,100,110,Active ingredient,citalopram ,consensus set annotator team,,50,60,Positive,Quantitative,"In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",consensus set annotator team,137,187
package-insert-section-77.txt,Active ingredient,digoxin ,consensus set annotator team,104,111,Active ingredient,citalopram ,consensus set annotator team,,89,99,Negative,Qualitative,"In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.",consensus set annotator team,134,183
package-insert-section-77.txt,Active ingredient,citalopram ,consensus set annotator team,89,99,Active ingredient,digoxin ,consensus set annotator team,,208,215,Negative,Qualitative,"In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.",consensus set annotator team,134,183
package-insert-section-78.txt,Active ingredient,Citalopram ,consensus set annotator team,229,239,Active ingredient,pimozide ,consensus set annotator team,,278,286,Negative,Qualitative,Citalopram did not alter the mean AUC or Cmax of pimozide.,consensus set annotator team,240,274
package-insert-section-79.txt,Active ingredient,citalopram ,consensus set annotator team,28,38,Active ingredient,warfarin ,consensus set annotator team,,90,98,Negative,Qualitative,"Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.",consensus set annotator team,51,86
package-insert-section-8.txt,Active ingredient,carbamazepine ,consensus set annotator team,5158,5171,Active ingredient,risperidone ,consensus set annotator team,,5218,5229,Positive,Qualitative,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS].",consensus set annotator team,5230,5288
package-insert-section-8.txt,Active ingredient,phenytoin ,consensus set annotator team,5173,5182,Active ingredient,risperidone ,consensus set annotator team,,5218,5229,Positive,Qualitative,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS].",consensus set annotator team,5230,5288
package-insert-section-8.txt,Active ingredient,rifampin ,consensus set annotator team,5184,5192,Active ingredient,risperidone ,consensus set annotator team,,5218,5229,Positive,Qualitative,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS].",consensus set annotator team,5230,5288
package-insert-section-8.txt,Active ingredient,phenobarbital ,consensus set annotator team,5198,5211,Active ingredient,risperidone ,consensus set annotator team,,5218,5229,Positive,Qualitative,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS].",consensus set annotator team,5230,5288
package-insert-section-80.txt,Active ingredient,citalopram ,consensus set annotator team,27,37,Active ingredient,ketoconazole ,consensus set annotator team,,50,62,Positive,Quantitative,"Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",consensus set annotator team,72,129
package-insert-section-80.txt,Active ingredient,ketoconazole ,consensus set annotator team,50,62,Active ingredient,citalopram ,consensus set annotator team,,27,37,Negative,Qualitative,"Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",consensus set annotator team,149,198
package-insert-section-81.txt,Active ingredient,citalopram ,consensus set annotator team,28,38,Active ingredient,metoprolol ,consensus set annotator team,,135,145,Positive,Quantitative,Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol.,consensus set annotator team,51,103
package-insert-section-83.txt,Active ingredient,tacrine ,consensus set annotator team,20,27,Active ingredient,theophylline ,consensus set annotator team,,33,45,Positive,Quantitative,Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold.,consensus set annotator team,46,161
package-insert-section-84.txt,Active ingredient,Cimetidine ,consensus set annotator team,0,10,Active ingredient,tacrine ,consensus set annotator team,,41,48,Positive,Quantitative,"Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively.",consensus set annotator team,11,77
package-insert-section-85.txt,Active ingredient,fluvoxamine ,consensus set annotator team,83,94,Active ingredient,tacrine ,consensus set annotator team,,66,73,Positive,Quantitative,"In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.",consensus set annotator team,155,209
package-insert-section-88.txt,Drug product,SEPTRA ,consensus set annotator team,0,6,Active ingredient,phenytoin ,consensus set annotator team,,45,54,Positive,Qualitative,SEPTRA may inhibit the hepatic metabolism of phenytoin.,consensus set annotator team,7,41
package-insert-section-88.txt,Drug product,SEPTRA ,consensus set annotator team,56,62,Active ingredient,phenytoin ,consensus set annotator team,,113,122,Positive,Quantitative,"SEPTRA, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%.",consensus set annotator team,99,199
package-insert-section-9.txt,Active ingredient,pimozide ,consensus set annotator team,2392,2400,Active ingredient,fluvoxamine ,consensus set annotator team,,2303,2314,Positive,Qualitative,"A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.",consensus set annotator team,2278,2326
package-insert-section-9.txt,Active ingredient,warfarin ,consensus set annotator team,2402,2410,Active ingredient,fluvoxamine ,consensus set annotator team,,2303,2314,Positive,Qualitative,"A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.",consensus set annotator team,2278,2326
package-insert-section-9.txt,Active ingredient,theophylline ,consensus set annotator team,2412,2424,Active ingredient,fluvoxamine ,consensus set annotator team,,2303,2314,Positive,Qualitative,"A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.",consensus set annotator team,2278,2326
package-insert-section-9.txt,Active ingredient,omeprazole ,consensus set annotator team,2451,2461,Active ingredient,fluvoxamine ,consensus set annotator team,,2303,2314,Positive,Qualitative,"A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.",consensus set annotator team,2278,2326
package-insert-section-9.txt,Active ingredient,phenytoin ,consensus set annotator team,2466,2475,Active ingredient,fluvoxamine ,consensus set annotator team,,2303,2314,Positive,Qualitative,"A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.",consensus set annotator team,2278,2326
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,3105,3116,Active ingredient,lorazepam ,consensus set annotator team,,3197,3206,Negative,Qualitative,Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.)in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.,consensus set annotator team,3236,3278
package-insert-section-9.txt,Active ingredient,lorazepam ,consensus set annotator team,3197,3206,Active ingredient,fluvoxamine ,consensus set annotator team,,3105,3116,Negative,Qualitative,Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.)in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.,consensus set annotator team,3236,3278
package-insert-section-9.txt,Active ingredient,ethanol ,consensus set annotator team,3578,3585,Active ingredient,fluvoxamine ,consensus set annotator team,,3675,3686,Negative,Qualitative,Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.)revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.,consensus set annotator team,3719,3800
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,3675,3686,Active ingredient,ethanol ,consensus set annotator team,,3578,3585,Negative,Qualitative,Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.)revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.,consensus set annotator team,3719,3800
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,3675,3686,Active ingredient,ethanol ,consensus set annotator team,,3578,3585,Negative,Quantitative,Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.)revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.,consensus set annotator team,3710,3767
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,4047,4058,Active ingredient,carbamazepine ,consensus set annotator team,,3953,3966,Positive,Qualitative,Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.,consensus set annotator team,3944,3973
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,4801,4812,Active ingredient,tacrine ,consensus set annotator team,,4784,4791,Positive,Quantitative,"Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.",consensus set annotator team,4873,4927
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,5416,5427,Active ingredient,clomipramine ,consensus set annotator team,,5455,5467,Positive,Qualitative,"Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.",consensus set annotator team,5326,5367
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,5416,5427,Active ingredient,clomipramine ,consensus set annotator team,,5455,5467,Positive,Qualitative,"Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.",consensus set annotator team,5326,5386
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,5416,5427,Active ingredient,amitriptyline ,consensus set annotator team,,5440,5453,Positive,Qualitative,"Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.",consensus set annotator team,5326,5386
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,5416,5427,Active ingredient,imipramine ,consensus set annotator team,,5471,5481,Positive,Qualitative,"Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.",consensus set annotator team,5326,5386
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,6834,6845,Active ingredient,digoxin ,consensus set annotator team,,6977,6984,Negative,Qualitative,Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.,consensus set annotator team,6887,6936
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,7199,7210,Active ingredient,propranolol ,consensus set annotator team,,7351,7362,Positive,Quantitative,Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.,consensus set annotator team,7286,7384
package-insert-section-9.txt,Active ingredient,fluvoxamine ,consensus set annotator team,7968,7979,Active ingredient,atenolol ,consensus set annotator team,,8084,8092,Negative,Qualitative,Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.,consensus set annotator team,8040,8080
package-insert-section-90.txt,Active ingredient,paroxetine ,consensus set annotator team,732,742,Active ingredient,atomoxetine ,consensus set annotator team,,780,791,Positive,Qualitative,"7.2 Effect of CYP2D6 Inhibitors on Atomoxetine

In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).",consensus set annotator team,771,826
package-insert-section-90.txt,Active ingredient,fluoxetine ,consensus set annotator team,744,754,Active ingredient,atomoxetine ,consensus set annotator team,,780,791,Positive,Qualitative,"7.2 Effect of CYP2D6 Inhibitors on Atomoxetine

In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).",consensus set annotator team,771,826
package-insert-section-90.txt,Active ingredient,quinidine ,consensus set annotator team,760,769,Active ingredient,atomoxetine ,consensus set annotator team,,780,791,Positive,Qualitative,"7.2 Effect of CYP2D6 Inhibitors on Atomoxetine

In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).",consensus set annotator team,771,826
package-insert-section-90.txt,Active ingredient,paroxetine ,consensus set annotator team,925,935,Active ingredient,atomoxetine ,consensus set annotator team,,962,973,Positive,Quantitative,"In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.",consensus set annotator team,951,1045
package-insert-section-90.txt,Active ingredient,fluoxetine ,consensus set annotator team,939,949,Active ingredient,atomoxetine ,consensus set annotator team,,962,973,Positive,Quantitative,"In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.",consensus set annotator team,951,1045
package-insert-section-90.txt,Active ingredient,atomoxetine ,consensus set annotator team,2481,2492,Active ingredient,midazolam ,consensus set annotator team,,2651,2660,Positive,Quantitative,"CYP3A Substrate (e.g., Midazolam)  Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.",consensus set annotator team,2628,2647
package-insert-section-90.txt,Active ingredient,atomoxetine ,consensus set annotator team,2788,2799,Active ingredient,desipramine ,consensus set annotator team,,2970,2981,Negative,Qualitative,"CYP2D6 Substrate (e.g., Desipramine)  Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine.",consensus set annotator team,2932,2966
package-insert-section-90.txt,Active ingredient,magnesium hydroxide ,consensus set annotator team,3783,3802,Active ingredient,atomoxetine ,consensus set annotator team,,3852,3863,Negative,Qualitative,"7.9 Drugs that Affect Gastric pH

Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.",consensus set annotator team,3839,3893
package-insert-section-90.txt,Active ingredient,aluminum hydroxide ,consensus set annotator team,3803,3821,Active ingredient,atomoxetine ,consensus set annotator team,,3852,3863,Negative,Qualitative,"7.9 Drugs that Affect Gastric pH

Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.",consensus set annotator team,3839,3893
package-insert-section-90.txt,Active ingredient,omeprazole ,consensus set annotator team,3823,3833,Active ingredient,atomoxetine ,consensus set annotator team,,3852,3863,Negative,Qualitative,"7.9 Drugs that Affect Gastric pH

Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.",consensus set annotator team,3839,3893
package-insert-section-91.txt,Active ingredient,fluoxetine ,consensus set annotator team,1654,1664,Active ingredient,atomoxetine ,consensus set annotator team,,1533,1544,Positive,Qualitative,"Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.",consensus set annotator team,1693,1728
package-insert-section-91.txt,Active ingredient,paroxetine ,consensus set annotator team,1666,1676,Active ingredient,atomoxetine ,consensus set annotator team,,1533,1544,Positive,Qualitative,"Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.",consensus set annotator team,1693,1728
package-insert-section-91.txt,Active ingredient,quinidine ,consensus set annotator team,1682,1691,Active ingredient,atomoxetine ,consensus set annotator team,,1533,1544,Positive,Qualitative,"Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.",consensus set annotator team,1693,1728
package-insert-section-91.txt,Active ingredient,fluoxetine ,consensus set annotator team,3818,3828,Active ingredient,atomoxetine ,consensus set annotator team,,3893,3904,Positive,Qualitative,"Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].",consensus set annotator team,3881,3920
package-insert-section-91.txt,Active ingredient,paroxetine ,consensus set annotator team,3830,3840,Active ingredient,atomoxetine ,consensus set annotator team,,3893,3904,Positive,Qualitative,"Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].",consensus set annotator team,3881,3920
package-insert-section-91.txt,Active ingredient,quinidine ,consensus set annotator team,3845,3854,Active ingredient,atomoxetine ,consensus set annotator team,,3750,3761,Positive,Qualitative,"Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].",consensus set annotator team,3856,3920
package-insert-section-91.txt,Active ingredient,quinidine ,consensus set annotator team,3845,3854,Active ingredient,atomoxetine ,consensus set annotator team,,3893,3904,Positive,Qualitative,"Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].",consensus set annotator team,3881,3920
package-insert-section-92.txt,Active ingredient,voriconazole ,consensus set annotator team,65,77,Active ingredient,sirolimus ,consensus set annotator team,,161,170,Positive,Quantitative,"Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects.",consensus set annotator team,131,241
package-insert-section-94.txt,Active ingredient,ketoconazole ,consensus set annotator team,226,238,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,183,350
package-insert-section-94.txt,Active ingredient,ketoconazole ,consensus set annotator team,226,238,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,226,350
package-insert-section-94.txt,Active ingredient,itraconazole ,consensus set annotator team,251,263,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,183,350
package-insert-section-94.txt,Active ingredient,itraconazole ,consensus set annotator team,251,263,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,226,350
package-insert-section-94.txt,Active ingredient,nefazodone ,consensus set annotator team,276,286,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,183,350
package-insert-section-94.txt,Active ingredient,nefazodone ,consensus set annotator team,276,286,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,226,350
package-insert-section-94.txt,Active ingredient,fluvoxamine ,consensus set annotator team,299,310,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,183,350
package-insert-section-94.txt,Active ingredient,fluvoxamine ,consensus set annotator team,299,310,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,226,350
package-insert-section-94.txt,Active ingredient,erythromycin ,consensus set annotator team,327,339,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,183,350
package-insert-section-94.txt,Active ingredient,erythromycin ,consensus set annotator team,327,339,Active ingredient,alprazolam ,consensus set annotator team,,194,204,Positive,Quantitative,"Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ",consensus set annotator team,226,350
package-insert-section-95.txt,Active ingredient,nefazodone ,consensus set annotator team,20,30,Active ingredient,alprazolam ,consensus set annotator team,,41,51,Positive,Quantitative,Coadministration of nefazodone increased alprazolam concentration two-fold.,consensus set annotator team,31,74
package-insert-section-96.txt,Active ingredient,fluvoxamine ,consensus set annotator team,20,31,Active ingredient,alprazolam ,consensus set annotator team,,90,100,Positive,Quantitative,"Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%, and decreased measured psychomotor performance.",consensus set annotator team,46,155
package-insert-section-97.txt,Active ingredient,cimetidine ,consensus set annotator team,20,30,Active ingredient,alprazolam ,consensus set annotator team,,77,87,Positive,Quantitative,"Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%. ",consensus set annotator team,31,154
package-insert-section-98.txt,Active ingredient,alprazolam ,consensus set annotator team,183,193,Active ingredient,imipramine ,consensus set annotator team,,43,53,Positive,Quantitative," The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.",consensus set annotator team,95,130
package-insert-section-98.txt,Active ingredient,alprazolam ,consensus set annotator team,183,193,Metabolite,desipramine ,consensus set annotator team,imipramine ,58,69,Positive,Quantitative," The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.",consensus set annotator team,95,130
package-insert-section-99.txt,Active ingredient,propoxyphene ,consensus set annotator team,20,32,Active ingredient,alprazolam ,consensus set annotator team,,79,89,Positive,Quantitative,"Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%. ",consensus set annotator team,33,155
